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ABSTRACT 
The first part of the thesis discusses the synthesis of six analogues of annona-
ceous acetogenins, as well as their cytotoxicity. The acetogenins are an intri-
guing class of bioactive natural compounds that have shown a selective cyto-
toxicity against cancerous cells and as such are considered promising new drug 
leads. The modular synthetic route allows the construction of the analogues 
with a variable central part containing heteroatoms, e.g., nitrogen or sulphur, 
and facile variation in stereochemistry with high stereoselectivity.  
The second part of the thesis concerns the enantioselective synthesis of 
amino acid derivatives, focusing on the asymmetric transfer hydrogenation via 
dynamic kinetic resolution in the synthesis of anti--amido--hydroxy esters. 
The conditions found afforded both alkyl- and aryl-products with high yields 
and high enantio- and diastereoselectivities. These compounds are valuable 
building blocks for constructing complex bioactive molecules, interesting to the 
pharmaceutical industy, and the conditions discussed allow two adjacent stereo-
centers in the product to be set in one step in water emulsions.  
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DME dimethoxyethane  
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DMPU 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
d.r. diastereomeric ratio 
ED50 effective dose, dose that produces desired effect in 50% of a 
population 
EDG electron donating group 
ee enantiomeric excess 
ent enantiomer 
equiv. equivalents  
e.r. enantiomeric ratio 
EWG electron withdrawing group  
HeLa cell line human epitheloid cervix carcinoma cell line 
HIV-1 Human Immunodeficiency Virus, type 1 
HKR hydrolytic kinetic resolution 
HMPA hexamethylphosphoramide 
HPLC high performance liquid chromatography  
HRMS high resolution mass spectrometry  
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IR infrared absorption spectroscopy  
KR kinetic resolution 
LA Lewis acid 
LDA lithium diisopropylamine 
LiHMDS lithium bis(trimethylsilyl)amide 
Me methyl  
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rt room temperature  
(S,S)-salenCo(II) (S,S)-N,N’-bis(3,5-di-tert-butylsalicylidene)-1,2-
cyclohexanediaminocobalt(II) 
SAR structure-activity relationship  
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TBAHS tetrabutylammonium hydrogensulfate  
TBAI tetrabutylammonium iodide 
TBDMS tert-butyldimethylsilyl  
TBDPS tert-butyldiphenylsilyl 
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TEAF triethylammonium formate 
TEBA benzyltriethylammonium chloride 
Teoc 2-(trimethylsilyl)ethoxycarbonyl 
TFA trifluoroacetic acid  
THF  tetrahydrofuran 
THP tetrahydropyran 
TLC thin layer chromatography  
TMS trimethylsilyl  
Ts tosyl, (4-toluenesulfonyl)  
TS transition state 
(S,S)-TsDPEN (1S,2S)-1,2-diphenyl-1-tosylamino-1,2-diamine-ethane 
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1. INTRODUCTION 
We are surrounded by chiral structures – chirality plays an important role in all 
biological systems, and has been proven vital in the agricultural, pharmaceutical 
and chemical industries. Active scientific interest towards chirality and its 
relevancy in pharmacology and therapeutics had its beginning in 1980s and 
1990s, despite the earlier pioneering work and discoveries of great minds like 
Pasteur, Fisher and others. Before the synthetic approach, chiral compounds 
were used as therapeutics unintentionally. For example, one of the earliest 
known cases where a chiral compound was used to cure a disease was of 
quinine and its antimalarial properties. Throughout the following decades and 
centuries, starting from the late 1620s, the story of quinine and 
other cinchona alkaloids can be traced. The knowledge of 
Peruvian Indian folk medicine that cinchona tree bark, which 
was unknowingly to its users rich in chiral alkaloids, could 
cure malarial fever was brought to Europe by returning 
missionaries.1 The struggles of chemists to synthesize quinine 
were rewarded only in 1944 when the first formal synthesis 
was reported by Woodward, 2  and the first stereoselective 
synthesis as late as 2001.3  
The high regard for enantiomeric compounds and the asymmetric synthesis 
thereof has increased with the widening knowledge of the mechanisms behind 
the bioactive molecules in the biological systems. A majority of the drugs 
manufactured industrially are chiral compounds and many of these are used as 
single enantiomers. Although the portion of racemate drugs has been declining 
over the last 30 years, they have not disappeared completely from the pharmacy 
scene.4 Most of the new drugs launched now are single enantiomers, the number 
has almost doubled from the 1980s to the 2000s.5 Also, the new drugs released 
as a single enantiomer are considerably more complex compared to the early 
days of industrial pharmacology. Thus, new methods for the synthesis of the 
bioactive compounds are always sought after. These methods also include 
synthesis from smaller ‘molecular building blocks’ or resolution of a chiral 
matter. Natural as well as unnatural amino acids and their derivatives are the 
most frequently used chirality pool. The synthesis of amino acid derivatives 
with anti-configuration is discussed in the chapter 3 of this thesis. In chapter 2, 
synthesis of more complex compounds is described, encompassing both new 
and known methods to set stereocenters. 
 
 
  
N
N
OMe
OH
quinine
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1.1. Kinetic resolution and  
Asymmetric Transformation 
Alongside with enantioselective synthesis, the separation of enantiomers from 
chiral matter has been a research area of great interest. Resolving an enantiomer 
from a racemate is often based on making and separating the diastereomeric 
derivatives and using double asymmetric induction. Here two non-enzymatic 
kinetic resolution methods are introduced: classical kinetic resolution (KR), 
parallel kinetic resolution (PKR), and an asymmetric transformation called 
dynamic kinetic resolution (DKR).6 In a KR a racemate, composed of enantio-
mers SS and SR, is subjected to a chiral reagent or a catalyst R* (Figure 1). On 
the time scale of this selective reaction, the enantiomers are not interconvertable 
(kinv = 0). One of the enantiomers is transformed into a product PR, while the 
other enantiomer SS will react considerably slower (kR>>kS), and can be re-
covered in a stereochemically enriched form. 
 
Figure 1. General reaction and energy diagrams of kinetic resolution. A) racemic 
mixture of substrates SS and SR, that are not interconvertable (kinv = 0); B) in the 
presence of a chiral reagent/catalyst R*, SR will transform into product PR in higher rate 
compared to SS (kR >> kS).   
 
 
The KR method will be discussed more in chapter 2, in which a bis-epoxide is 
subjected to KR conditions towards the synthesis of bioactive analogues of 
acetogenins. 
PKR is an interesting development of the KR method where two resolving 
agents are used to resolve enantiomers by performing two kinetic resolutions 
simultaneously. These resolving agents are chiral reagents or catalysts, often 
quasi-enantiomers – compounds relatively similar in their build-up and some-
times almost enantiomeric in their nature. The substrate SS reacts faster with one 
 
 
                
Ss kS
kR
kR >> kSSR PR max 50% yield if
+
R*
R* PS
  
kinv = 0 
!G!!" !G!""
!!G!"
SR SS 
PS PR 
E 
 
 
 
 
 
  
v 
kinv = 0 
!G!!" !G!""
!!G!"
SR SS 
PS PR 
E 
A) B) 
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of the agents R1*, and SR reacts faster with the other agent R2* (Figure 2), both 
enantiomers are converted into two different products.  
 
Figure 2. General reaction and energy diagrams of parallel kinetic resolution. A) 
Racemic mixture of substrates SS and SR, that are not interconvertable (kinv = 0); B) SS 
reacts faster with R1* and forms P1S (k1S > k2S), and SR reacts faster with R2* and forms 
P2R (k2R > k1R).  
 
 
In DKR a racemic mixture of enantiomers SS and SR that readily interconvert 
(racemize) to each other, are subjected to a chiral reagent or catalyst R* (Figure 
3). The substrates react with the resolving agent at different rates, and if for the 
one enantiomer SR the transformation rate to the product is considerably higher 
than for the other (kR>kS) and the inversion rate is kinv>>kR, product PR can be 
afforded in up to 100% yield. 
 
DKR will be discussed in chapter 3, where asymmetric transfer hydrogenation 
via DKR is shown in the synthesis of amino acid derivatives. 
 
 
  
 
 
 
              
SR k1R
k1S
SS P1S
+
R1*
R1*
k2R
k2S
R2*
R2*
P2R P1R
P2S
k1S = k2R >> k2S = k1R
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!!G!"!#
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Figure 3. General reaction and energy diagrams of DKR. A) Racemic mixture of 
substrates SS and SR, that readily enantiomerize; B) SR reacts with R* and forms PR 
faster than SS (kR>kS), while the substrates interconvert to each other (kent>>kR).  
 
 
A nice example to illustrate these resolution methods is of acylation of a 
racemic secondary alcohol 1.1 (Scheme 1). In 1998 Fu and co-workers resolved 
1.1 by acylation via KR in the presence of a planar-chiral DMAP derivate 
catalyst (cat. A) and an achiral acyl donor. The product 1.2 was achieved in 
excellent enantiomeric selectivity with 95% ee and with 52% conversion.7 More 
than a decade later the same substrate was subjected to PKR conditions by 
Duffey et al. in the presence of two chiral catalysts (phosphine cat. B and 
DMAP-derived cat. C) and two different achiral acyl donors.8 Two products 1.3 
and 1.4 were isolated along with some of the recovered starting material 1.1 
with 8% ee (for ideal PKR this would be 0% ee). For the products enantio-
selectivities 87% ee and 76% ee were determined after hydrolysis.  
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Scheme 1. Enantiomeric acylation of racemic alcohol 1.1 via KR, PKR and DKR. 
 
 
Fu and co-workers continued their studies on resolutions of secondary alcohols 
and recently reported a DKR of 1.1, where ent-1.2 was afforded with a high 
yield of 94% and with a good enantioselectivity of 90% ee. They used the same 
acylation catalyst as earlier (cat. A) but in combination with a ruthenium 
complex (cat. D) as a racemization catalyst.9 They successfully demonstrated 
this approach on a scope of aryl and alkyl carbinols, and showed it even to be 
superior to an enzymatic DKR of secondary alcohols in the case of substrates 
with branched substituents.  
 
 
1.2. The aim of the thesis 
There are two aims in this thesis.  
Firstly, in chapter 2, which discusses the synthesis of analogues to natural 
compounds called acetogenins, the aim is to synthesize the analogues with high 
stereoselectivity and assess their bioactivity. A new approach of hydrolytic 
kinetic resolution of bis-epoxides is employed, where the afforded product has 
two remote stereocenters set with high enantiomeric- and diastereomeric selecti-
vity. 
In chapter 3, the work to find a general method for the asymmetric transfer 
hydrogenation of aryl and alkyl -amido--keto esters via DKR is detailed, 
which would render the products anti--amido--hydroxy esters in high stereo-
selectivity and yields. 
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2. SYNTHESIS OF THIO- AND AZA-ANALOGUES 
OF ANNONACEOUS ACETOGENINS 
(Papers I, II and III) 
 
2.1. Introduction 
In this work a stereoselective synthesis of six non-THF analogues of annona-
ceous acetogenins is reported, from which four are aza- and two thio-analogues 
(Figure 4). Their biological activity is assessed on a model tumorous cell line. 
The key steps, such as the synthesis of amino alcohols and the kinetic resolution 
of bis-epoxides are discussed.  
 
 
Figure 4. Aza-analogues A–D and thio-analogues E and F of acetogenins to be 
synthesized. 
 
Annonaceous acetogenins belong to an intriguing class of natural bioactive 
compounds. 10  The most significant bioactivities include cytotoxicity, anti-
bacterial, 11  antiproliferative, 12  insecticidal, antifungal, 13  immunosuppressive, 
and anti-angiogenesis14  effects, among others reported. The acetogenins are 
found in a tree family Annonaceae from the order Magnoliales, which are 
native to mostly tropical and sub-tropical regions. Before the 1980s, investi-
gations of the Annonaceae concerned other bioactive compounds found in the 
family, e.g., isoquinoline alkaloids.15 Since Jolad et al. isolated uvaricin (2.1, 
Figure 5) with anticancer activity from Uvaria acuminata in the 1980s,16 the 
acetogenins have been under increasing interest from the scientific world. The 
selective cytotoxic activity against cancer cells has put them on their way 
towards being potential lead compounds for new anti-cancerous drugs.  
 
 
Figure 5.  Uvaricin was the first isolated acetogenin. 
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2.1.1. Structural characterization of annonaceous acetogenins 
The typical acetogenin structure consists of a long unbranched aliphatic chain, 
centrally positioned one to three THF or THP rings,17 adjacent hydroxyl groups 
and a terminal methyl-substituted ,-unsaturated -lactone ring. There can be a 
variation in the stereochemistry and in the number and position of hydroxyl 
groups within the structure. The aliphatic chain may also contain double18 or 
triple19 bonds, and occasionally keto- or acetoxy-groups instead of hydroxyl 
groups. In Figure 6, a selection of acetogenins is shown to illustrate the 
structural variability within the family. Bullatacin (2.2) has two adjacent THF 
rings and is considered one of the most potent of the acetogenins. Annonacin 
(2.3) represents the type of acetogenin with only one THF ring and mucosin 
(2.4) a more rare variant, containing both THF and THP rings. The next three 
compounds 2.5–2.7 are proposed to be precursors in biosynthesis towards the 
final acetogenin structures and can possess lower bioactivity. To date, more 
than 400 different acetogenins have been identified – the structures of aceto-
genins can vary greatly even in an extract from a common source plant. For 
example, twenty structurally different acetogenins could be isolated from the 
seed extracts of Annona squamosal.20 Also, the amount extracted depends on 
the region in the source plant (bark, seeds, roots or fruits) and on the season the 
plant samples are collected. To give an example on the laborious nature and 
relatively low productivity of extracting acetogenins from plant material, 
another research group was able to isolate 309 mg of a mixture of seven diffe-
rent acetogenins from 10 kg of seeds of A. squamosa. 21  In addition to the 
tedious isolation and identification of compounds being time and material 
consuming, some acetogenins in the mixture cannot be fully separated and 
remain as a mixture of isomers.  
To overcome these obstacles and to have pure compound in the amounts 
needed for subsequent research, various synthetic routes have been developed 
for both mimics of natural acetogenins and their altered non-natural analogues. 
The latter are of great interest in elucidating the structure-activity relationship 
(SAR). The final consensus on SAR is yet to be established – with new 
approaches in studies, the world of acetogenins continues to unravel new 
discoveries.  
 
 
22 
 
Figure 6. Illustration of the structural diversity in isolated natural acetogenins. 
 
 
In the 1990s, McLaughlin and co-workers divided the isolated acetogenins into 
six general types (Figure 7, a). This tentative classification of acetogenins was 
based on the central fragment of the acetogenin compounds, and can branch out 
as many subtypes, according to differences in the remaining fragments in the 
structure, e.g., -lactone ring (Figure 7, b). The ever-growing number and 
variability of structures synthesized contribute to the number of subtypes. The 
general classification of acetogenins according to structure would be then as 
follows: 
1. Linear acetogenins 
2. Epoxy-acetogenins 
3. Mono-THF acetogenins 
4. Bis-THF acetogenins 
4.1 non-adjacent bis-THF acetogenins 
5. Tri-THF acetogenins 
6. THP acetogenins 
6.1 THP and THF acetogenins 
6.2 non-adjacent THP-THF acetogenins 
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Figure 7. a) Central fragments of acetogenins, b) terminal lactone ring units. 
 
 
Although the level of potency may vary depending on the cell line used for the 
studies, it has been shown that the adjacent bis-THF acetogenins are the most 
potent in the acetogenin family to date. They are followed by the non-adjacent 
bis-THF and then mono-THF acetogenins on a scale of decreasing potency. 
Therefore, a lot of attention has been focused on synthesizing THF-containing 
acetogenin structures to mimic the most potent acetogenins. 
 
 
2.1.1.1. Unnatural analogues of non-THF acetogenins 
In the search of the optimal structure for the target bioactivity, the synthesis of 
unnatural non-THF analogues has emerged. In these compounds heteroatom-
containing fragments have substituted the THF units, eliminating at least two 
stereocenters (Figure 8). Compound 2.8 is a linear derivate of bullatacin, with 
missing ethyl bridges of THF rings, and 2.9 is a methylated amide unit bearing 
derivate, both with comparable bioactivities to each other.22 Just recently the 
same research group reported the compound 2.10 with two lactone units.23 This 
symmetric analogue was achieved by opening two equivalents of the racemic 
epoxide bearing the lactone ring with ethylene diamine. The N,N’-benzylated 
diamine analogue 2.1124 was first of its kind that incorporated an amine moiety 
into the alkyl chain. Unfortunately, no bioactivity was reported for the last two 
analogues.  
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Figure 8. Selection of non-THF acetogenin analogues. 
 
2.1.2. Bioactivity and related effects of acetogenins 
The acetogenins are classified as one of the most potent NADH-ubiquinone 
oxidoreductase (Complex I) 25  inhibitors in mitochondrial electron transport 
system, as well as inhibitors of NADH oxidase of plasma membranes of cancer 
cells,26 interrupting ATP synthesis. This, in turn, may lead to cell death by 
either apoptosis or necrosis. Although it is known that the target area for the 
acetogenins is the subunit ND1 in the complex I, the direct site of action is still 
under debate. There have been specifications in the models of binding to the 
active sites in the enzyme, trying to clarify the mode of action. In 1998, 
McLaughlin and co-workers were first to suggest a general model, which 
describes how the acetogenins, lateral to the complex I, diffuse into the 
membrane bilayer and adopt a certain conformation [Figure 9, 1)]. 27  They 
proposed that while the lipophilic long alkyl-chains are embedded in the 
membrane, the THF rings with flanking hydroxyl groups act as a hydrophilic 
‘anchor’ in the membrane-plasma interface and the lactone ring alone interacts 
with the protein’s active site. Any branching in the hydrocarbon chain was 
shown to cause a loss of activity.28  
In the subsequent years, Miyoshi and colleagues brought forward several 
new approaches to the model, of which two are shown in Figure 9 [2) and 3)]. 
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Figure 9. Evolution of the binding models of acetogenins to complex I: 1) the first 
binding model by McLaughlin and co-workers in y. 1998; 2) model showing two active 
sites and the relevance of the length of the linker, by Miyoshi and co-workers in y. 
2008; 3) model by Miyoshi in y. 2011 confirming the model with two active sites.  
 
 
The authors made modifications to the acetogenin structure by changing the 
length of the alkyl linker and the number of THF rings, and proposed that there 
could be two binding sites in the enzyme, and that the acetogenin molecule has 
to occupy these simultaneously to exert inhibition on enzyme activity [Figure 9, 
2)].29 This was confirmed a few years later by a study using a photoreactive 
acetogenin mimic, which showed that in the subunit ND1, there are two binding 
pockets [site A and B, Figure 9, 3)] where the THF rings and the lactone ring 
bind. 30  Recently, a crystal structure of complex I from bacterium Thermus 
thermophilus was reported.31 Thus, novel insights about binding of acetogenins 
in complex I sites may emerge.  
The main focus in studying acetogenins has been their anti-cancerous effect. 
There is strong evidence of selectivity between normal tissue and tumorous 
ones. McLaughlin and co-workers have also reported the cytotoxicity of 
acetogenins against multidrug resistant (MDR) cells.32 The action against MDR 
could be derived from the ability to lower ATP levels in the cells – the MDR 
cells often support ATP-fuelled plasma membrane glycoproteins, which export 
anti-cancerous compounds from the cell before they can execute their effect. 
But there is still much to be elucidated concerning the mode of action of the 
annonaceous acetogenins in cancer cells before any certain conclusions could 
be drawn.  
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Additionally, the acetogenins have been shown to form clusters with cations 
like Ca2+ and K+, which disrupt the ionic balance in the cell.33 This can also be 
linked to cell death 34  as elevated Ca2+ levels are reported to stimulate a 
cytotoxic cascade in many cell lines. It has been proposed that chelation of the 
acetogenins to Ca2+ ions may facilitate the penetration of the cell membrane or 
the mitochondrial membrane, and therefore may explain why some acetogenin 
analogues, based on their chelation ability, are more cytotoxic than others.35  
For centuries people, native to the habitat of the Annonaceae family, have 
been using these plants in their diet in various forms. Even nowadays, there are 
many products for internal and external use that contain annonaceous plant 
material in different concentrations and purity, and are claimed to have some 
curative potency.36 More so, whole series of commercial products have been 
established on the remedial potency of annonaceous plants. Coupled with this 
long history of human consumption, the studies concerning the neurotoxicity of 
acetogenins, should be of high interest. There have been reports claiming that 
the acetogenins cross the blood-brain barrier and cause atypical parkinso-
nism.37,38,39 This is an aspect worth examining, especially if the acetogenins are 
to develop into marketable drug candidates. Champy et al. showed a similar 
pattern of neurodegeneration on treated mice.40 The mice were subjected to 
doses of an acetogenin called annonacin over a period of time and the observed 
effect was similar to the atypical parkinsonism, which is claimed to have been 
caused by consuming annonaceous plants. On the other hand, these plants also 
contain other bioactive compounds, like isoquinolic alkaloids, that can also 
impart neural damage. Thus, a combinatory effect of multiple toxins might be 
responsible for these reported effects, rather than the acetogenins alone.  
 
 
2.1.3. Synthetic examples of acetogenin analogues 
The interest in synthesis of acetogenins and their analogues has followed an 
explosive trend in the last two decades.41 As the acetogenins have multiple 
stereogenic centers, the introduction of chirality into the compounds is often the 
key step. The first total synthesis was reported by Hoye et al42 in 1991 for a 
stereoisomer of uvaricin (2.1), the acetogenin that was also the first isolated. In 
their synthetic route the four stereogenic centers in the central region were 
introduced by the chiral starting material L-(+)-diethyl tartrate, and D-(-)-
diisopropyl tartrate catalyzed Sharpless asymmetric olefin epoxidation. In the 
1990s, synthesized acetogenins were mostly mimics of isolated acetogenins and 
made often for the purpose of elucidating the stereochemistry of the parent 
compounds. From this high diversity of known acetogenin structures many 
theories concerning bioactivity have risen. For now, chemical synthesis has 
proven more effective in producing either mimics of the natural compounds or 
new unnatural analogues for the study towards drug lead compounds.  
Since our synthetic targets in the current work are unnatural non-THF 
analogues, a handful of representative examples of the synthesis of non-THF 
analogues are highlighted.  
27 
Yao and Wu with co-workers described a series of acetogenin analogues 
containing ethylene glycol units, where the ethylene bridges in the THF rings 
have been removed when compared with the bis-THF acetogenins.43 The most 
bioactive analogue of the series proved to be 2.8 (Scheme 2), furnished with a 
hydroxyl group in position 4 like in many potent acetogenins (e.g., bullatacin 
2.2).44 One of the key fragments 2.14 was afforded after a three-step sequence 
starting from methyl pent-4-enoate 2.12 and (S)-O-tetrahydropyranyl lactal and 
a subsequent oxidation of 2.13 with m-CPBA, followed by Jacobsen’s 
hydrolytic kinetic resolution of the formed racemic epoxide. Then aldehyde 
2.15 was subjected to Wittig reaction, and after hydrogenation and deprotection, 
diol 2.16 was obtained. Diol 2.16 was regioselectively O-alkylated with 2-
benzyloxyethyl iodide to afford compound 2.17. After protecting the secondary 
alcohol as a MOM ether, the terminal benzyl-protecting group was removed by 
reductive cleavage. Compound 2.18 was obtained after coupling reaction with 
(R)-epichlorohydrin. Then lithium 1,7-octadiyne was treated with 2.18 in the 
presence of BF3Et2O to afford 2.19, which was then subsequentially lithiated 
and C-alkylated with epoxide 2.14. The triple bonds in the product were 
reduced by diimide and after deprotection, end-product 2.8 was obtained.  
 
 
Scheme 2. Synthesis of bis-ether analogue 2.8. 
 
 
A second example on synthesis is for N,N’-benzylated diamine compound 2.11 
(Scheme 3).24 This compound was first of the linear aza-analogues reported. 
The synthesis started with the same aldehyde 2.15 as in the previous example. 
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After elongation of aldehyde 2.15 with a Wittig reaction, the afforded 2.20 was 
used for alkylating the lactone ring 2.21 over an iodide intermediate to yield 
2.22. Then, over six steps, the diol moiety was deprotected and converted into 
an epoxide 2.24 over compound 2.23. The synthesis of the amino alcohol 
intermediate 2.26 was also started from the aldehyde 2.15. After Wittig 
reaction, hydrogenation and a subsequent deprotection, conducted similarly to 
the previous example,44 diol 2.16 was afforded. Diol 2.16 was then converted 
into epoxide 2.25 that was subsequently opened by a N,N’-benzylated 
ethylenediamine, obtaining 2.26. The compound 2.26 was then coupled with 
epoxide 2.24 to yield the end-product 2.11. Unfortunately, the authors did not 
discuss debenzylation or the possible bioactivity of the synthesized analogue. 
 
Scheme 3. Synthetic scheme for N,N’-benzylated analogue 2.11. 
 
 
A third example is from Miyoshi and co-workers, who mainly focused on bis-
THF analogues. An interesting example of their synthesis schemes is the 
analogue 2.34 with a shortened alkyl ‘tail’ (Scheme 4). 45  The synthesis of 
intermediate 2.29 started by reacting t-butyl acetate 2.27 with trans-1,4-
dibromo-2-butene (2.28) by employing a strategy developed by Hoye and Ye.46 
This was followed by a reduction with DIBALH and an extension of the formed 
dialdehyde by Witting olefination. After a reduction of 2.29 with DIBALH, 
double Sharpless asymmetric epoxidation ensued. This was followed by 
silylation of the hydroxyl groups and a Sharpless asymmetric dihydroxylation 
of the remaining double bond, yielding compound 2.30. The THF rings were 
formed via a ‘‘inside-out’’ epoxide cascade reaction by treating 2.30 with tri-
fluoroacetic acid. The remaining secondary hydroxyl groups were tosylated and 
epoxide was formed after treatment with TBAF and K2CO3. The formed 
epoxide was then opened by catalytic hydrogenation with Pd/C and after 
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another conversion to an epoxide in the presence of excess TBAF, 2.31 was 
obtained. The epoxide in 2.31 was opened by lithium (trimethylsilyl)acetylide, 
affording 2.32 after desilylation. The compound 2.32 was coupled with vinyl 
iodide 2.33, catalyzed by Pd(0). The iodide 2.33 was prepared by a previously 
reported method.42 After hydrogenation using a Wilkinson’s catalyst and a 
thermal elimination of the sulphide moiety, the end-product 2.34 was obtained 
in a moderate yield.  
 
 
Scheme 4. Synthesis of bullatacin analogue with a shortened aliphatic chain. 
 
 
The analogue 2.34 exhibited only somewhat lower bioactivity compared to 
bullatacin, suggesting that the long alkyl tail might not be essentially important 
for the activity. 
 
 
2.1.4. Introduction of remote stereocenters 
The acetogenin structures often bear a pair of remote stereocenters, separated by 
11 bonds or more. Although efficient methodology for remote asymmetric 
induction has been reported for certain compounds,47 synthesizing a flexible 
acyclic compound bearing stereocenters more than four or five bond lengths 
apart in high stereoselectivity is still challenging. 48  Thus, in most of the 
synthetic routes of acetogenins, the critical fragments with remote stereocenters 
have been assembled from smaller chiral building blocks instead of preparing 
them as one unit. We sought an approach that would allow the introduction of 
more than one stereocenter in one step with high enantioselectivity, which 
shortens synthetic routes and would be cost efficient. 
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2.1.4.1. Kinetic resolution of terminal mono- and bis-epoxides 
After some exploration, we turned to Jacobsen’s kinetic resolution (KR) of 
epoxides that according to literature provides excellent stereoselectivity.49 The 
hydrolytic kinetic resolution (HKR) of terminal mono-epoxides is a well-
established method originally introduced by Jacobsen and co-workers (Scheme 
5).50 In the presence of an activated chiral (salen)Co(III) catalyst51 and water, 
one enantiomer of the racemic epoxide is opened to afford the enantiomerically 
enriched diol and the unreacted epoxide. Many research groups have 
contributed to this method and a wide substrate array has been created. Also 
nucleophiles other than water have been shown to give high enantioselectivities 
and high yields in the kinetic resolution52 and consequently, many synthetic 
routes of bioactive compounds have been utilizing this method.53   
 
 
Scheme 5. Kinetic resolution of terminal epoxides. 
 
 
Despite of the different nucleophiles working well under HKR conditions, water 
has remained the most popular one, being environmentally benign, cost-
effective and safe. Also, the resultant hydrolysis products are highly useful in 
the syntheses of more complex compounds. Both (R,R)-(salen)Co(II) and (S,S)-
(salen)Co(II) are commercially available, making the synthesis of opposite 
enantiomers easily executable.  
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Scheme 6. Mechanism proposed by Jacobsen for HKR of terminal epoxides.54 
 
 
Jacobsen’s mechanistic investigations suggest a co-operative action between 
two (salen)Co(III) catalysts in the rate determining step (Scheme 6).54 Firstly, 
the (salen)Co(II) complex is activated in the presence of air with a mild Lewis 
acid, e.g., AcOH, to form a pre-catalyst (salen)Co(III)OAc. The HKR reaction 
is promoted by this complex, which has a Lewis acidic character, by binding to 
the epoxide. A second (salen)Co(III)OAc complex is hydrolyzed to 
(salen)Co(III)OH, which acts as a nucleophile delivering agent to the epoxide 
bound to (salen)Co(III)OAc. Negligible amount of counterion addition product 
can form (up to 4 mol%) when complex (salen)Co(III)OAc acts as a 
nucleophile instead of (salen)Co(III)OH. The epoxide is bound to the complex 
with increased Lewis acidic character, which depends on the counterion (here 
OAc). A transition state (TS) for bimetallic epoxide opening is shown in Figure 
15. The hydrolysis step is relatively fast and the racemic epoxide is resolved 
into enantiomerically pure diol and epoxide.  
Interestingly, reports of the use of bis-epoxides as KR substrates are 
relatively rare. Jacobsen and co-workers were one of the first to report a HKR 
of a racemic bis-epoxide, but lacking a meso isomer.49d The meso isomer, which 
allows easier asymmetric bidirectional derivatization after KR, was investigated 
by Kitching and co-workers in the synthesis of insect sex pheromones,55 but 
unfortunately without reporting the assessment of stereoselectivity, which was 
presumably assumed to correlate with the literature data.  
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Scheme 7. HKR of bis-epoxides. 
 
 
The substrate bis-epoxide (Scheme 7) consist of three isomers: 50% of (R,S)-
meso isomer, 25% of (S,S)-isomer and 25% of (R,R)-isomer. After subjecting 
this isomeric mixture of the bis-epoxide to HKR conditions in the presence of 
the (S,S)-(salen)Co(III) catalyst, a statistical mixture of products is afforded – 
epoxy diol up to 50% theoretical yield, 25% of unreacted (S,S)-bis-epoxide and 
25% of (R,R)-tetrol.  
 
 
2.1.4.2. Sharpless asymmetric dihydroxylation of olefins 
Sharpless asymmetric dihydroxylation (AD) of olefins56 is also a well-known 
method and has often been employed in the synthesis of acetogenin analogues. 
Symmetrical dienes can be submitted to double AD (Scheme 8), which yields 
highly enantiomerically enriched tetrols for further derivatization. 57  For 
subsequent asymmetric bidirectional derivatizations, the second AD can be 
postponed to further along the synthesis route. AD, as well as KR of bis-
epoxides, can be considered as establishing remote stereogenic centers with a 
set conformation, by synthesis that is independent of existing stereogenic 
centers, i.e. catalyst control. 
 
 
Scheme 8. Double-AD of dienes. 
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2.1.5. Thio-compounds as bioactive molecules 
Thio-moieties have not been reported in natural acetogenins. But in many other 
natural bioactive compounds sulfur atoms are often integrated in the structural 
framework.58 For example, cyanobacterial compound largazole, which contains 
a thioester fragment in its structure, shows enhanced biological activity against 
selected cancerous cell-lines.59  
Although, the mode of binding of the acetogenins to the active site in 
complex I has yet to be elucidated, the importance of hydrogen bonding in the 
enzymic site has been agreed upon. Recently, it has been confirmed that sulfur 
can also act as a considerable hydrogen bond donor.60 It was shown that the 
divalent sulfur in dimethyl sulfide could form a H-bond, which, although 
weaker, is still comparable to H-bond with oxygen in dimethyl ether. Thus, we 
were intrigued to compile novel analogues of acetogenins where thio moieties 
are embedded into the aliphatic chain, but are otherwise structurally reminiscent 
of the aza-analogues. With their somewhat reduced ability to form H-bonds, the 
importance of the central region and the associated H-bonding could be 
assessed.  
 
 
2.2. Results and discussion 
The ethylene glycol analogue 2.8 with its retained inhibition ability and the 
N,N’-benzylated diamine analogue 2.11 inspired us to plan a series of 
acetogenin analogues and assess their bioactivities. We envisioned a highly 
stereoselective convergent synthetic route, which could be easily applicable for 
all analogues planned. During the course of the work, four aza-analogues A D  
(Figure 10) with a hydroxyl group at position C-4 where synthesized. In 
addition, two thio-analogues E and F were also prepared and furthermore, the 
cytotoxicities of E and F were compared to the aza-analogues A–D.  
 
 
Figure 10. Aza analogues A–D and thio analogues E and F of acetogenins to be 
synthesized. 
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We began our investigations with the aza-analogues. The general retrosynthetic 
scheme is shown in Scheme 9. One of the key elements in the synthesis route 
was the installation of the relevant stereochemistry. The compilation of the 
structure was planned according to a convergent, modular synthetic scheme. 
The four modules, i) twelve carbons long alkyl chain termed as the ‘‘tail’’, ii) 
central region, with changeable amine fragment (or thio fragment, shown here 
as Y), iii) ‘‘spacer’’, which joins the central and the terminal region, and iv) 
terminal butenolide moiety, were planned to be synthesized separately and 
joined together at different stages of the route. The planned analogues contained 
four stereocenters – one in the ‘‘tail’’, two in the ‘‘spacer’’ region and one in 
the butenolide. If we were to follow through with the modular synthesis plan, a 
method was needed to introduce two remote stereocenters ten carbon atoms 
apart in the ‘‘spacer’’ region. Usually this is overcome by coupling of the two 
chiral fragments, or using asymmetric induction. 61  As discussed above, es-
tablishing two stereocenters that are more than three bonds apart can be 
challenging, let alone in one step. We considered various approaches to intro-
duce stereochemistry, and two methods were chosen as the most suitable: 
Jacobsen’s hydrolytic kinetic resolution (HKR) of terminal epoxides and 
Sharpless asymmetric dihydroxylation (AD) of olefins. The benefits of these 
approaches were addressed above.  
 
 
Scheme 9. General retrosynthetic plan for the analogues to be synthesized.  
Y = aza- or thio-fragment. 
 
 
2.2.1. Hydrolytic kinetic resolution of bis-epoxides 
HKR of terminal bis-epoxides was employed to introduce the two remote 
stereocenters in the ‘’spacer’’ region. KR of bis-epoxides was investigated more 
closely in the Paper II. A scope of aryl and alkyl substrates was prepared and 
subjected to HKR and aminolytic kinetic resolution conditions (Scheme 10). 
The relative and absolute stereochemistry was determined by chiral HPLC and 
by the Mosher ester method, respectively. Excellent enantiomeric ratios were 
obtained for the afforded epoxy diols and epoxy amino alcohols – for most 
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products the er was 99.9:0.1 and only for one substrate a marginally lower er 
value of 99.2:0.8 was obtained. 
 
 
 
 
Scheme 10. Scope of HKR of bis-epoxides. 
 
 
The bis-epoxide 2.36 used in the synthetic route was obtained after oxidation of 
diene 2.35, and consists of three isomers: 50% of the meso isomer (R,S), 25% of 
(S,S)-isomer and 25% of (R,R)-isomer (Scheme 11). This isomeric mixture of 
the bis-epoxide was then subjected to HKR in the presence of the (S,S)-
(salen)Co(III) catalyst with 1 equiv. of water as the nucleophile. Our target 
product was the epoxy-diol 2.37, arising from the meso stereoisomer. The 
(R,R)-bis-epoxide is opened into a tetrol and (S,S)-bis-epoxide remains un-
affected in the reaction. These products were easily separated on column 
chromatography after HKR. Various approaches were considered in order to 
find the best way to assess the relative stereochemistry of the epoxy-diol 2.37. 
Since the two stereocenters in the epoxy-diol are separated by 11 bonds, the 
NMR spectra of 2.37 would be indistinguishable from possible diastereomers. 
Thus in the hope of assessing both enantiomeric and diastereomeric selectivity 
for 2.37, HPLC analysis on a chiral column was chosen. The resolution of the 
remote chiral centers can also pose a problem on chiral columns. Thus, UV-
active derivatives were made and compared with their enantiomers, which were 
achieved following identical synthetic routes, only in the presence of the HKR 
catalyst with an opposite stereochemistry.  
 
 
Scheme 11. Synthesis of epoxy-diol 2.37 via HKR of bis-epoxide 2.36. 
 
 
Fortunately, converting the epoxy diol 2.37 into the tosylate derivative 2.38 was 
already included as a step in the synthesis route of the analogues. As it 
conveniently bears a UV-active group next to one of the chiral centers, it was 
analyzed on chiral HPLC affording an isomeric ratio of 97:3 by comparing it 
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with its enantiomer (Scheme 12). The ratio could not be interpreted as er, 
because we could not be sure that the chiral center incorporated in the epoxide 
was discriminated on the column. Thus, to have a clear resolution of that chiral 
center, we oxidized the secondary alcohol in tosylate 2.38 into a ketone and 
opened the epoxide with naphthalene thiol, a second UV derivatizing reagent, to 
afford 2.39. After comparing 2.39 to its enantiomer, a gratifyingly high er 
99.7:0.3 was afforded. If assuming that only the chiral center C-OH in 2.38 was 
discriminated on the chiral column, and not the one incorporated in the epoxide, 
the 3% of the isomer detected must have had (S)-orientation. The analysis of 
2.39 showed negligible amount of an enantiomer, which indicates that the chiral 
center in the epoxide moiety in 2.37 also has (S)-configuration. Following this 
reasoning, the ratio 97:3 had to then show a presence of a diastereomer to 2.38 
derived from (S,S)-bis-epoxide and according to the er 99.7:0.3, negligible 
amount of enantiomer to the epoxy-diol 2.37. The presence of the (R,R)-dia-
stereomer was reasoned to be less than 0.3%, which was indicated by the HPLC 
analysis of 2.39. 
  
 
Scheme 12. Determining er and dr of epoxy diol 2.37 via derivatization. 
 
 
A second approach was to open the epoxy-diol 2.37 directly with 2-naphthalen-
ethiol (Scheme 12). A ratio 99.7:0.3 was achieved for 2.40 after HPLC analysis, 
which matches the er for 2.39.  
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2.2.2. Synthesis of amino-alcohols 
We then focused on the epoxide opening reaction with various amine-moieties 
as nucleophiles. The epoxide 2.41 (Scheme 13) was smoothly opened by a 1,2-
ethylenediamine fragment but attempts to use the afforded amino alcohol 2.42 
as a nucleophile in a second epoxide opening to obtain 2.43 proved to be 
inefficient under the same reaction conditions.  
Scheme 13. Synthesis of amino alcohol 2.42 and an attempt towards symmetric product 
2.43. 
 
 
The transformation was then investigated more closely. We reasoned that, either 
the amine moiety with the long alkyl chain was not nucleophilic enough, or the 
hydrophilic amino alcohol moiety with lipophilic chain contributes to the 
formation of micelles, thus obstructing the reaction from proceeding. In order to 
enhance the reactivity of the amine moiety, different N-protecting groups (N-
Pg) were studied. For this tosyl (Ts), benzyl (Bn), methyl (Me) and nosyl (Ns) 
groups were chosen. Also, different reaction conditions were explored, in-
cluding phase transfer catalysis.62 At first, the epoxide 2.41 was opened with 
either monoamine or ethylene diamine moiety, furnished with appropriate N-
Pgs, to afford amino alcohols 2.44, 2.46, 2.48, additionally to aforementioned 
2.42, and 2.50, 2.52, 2.54, 2.56, and 2.58, respectively (see Paper III and 
Experimental section 2.4 in the thesis for details). Then the formed amino 
alcohols were used as nucleophiles in the second epoxide opening reaction with 
2.41 or 2.60 (Table 1).  
For the unprotected amino alcohol 2.42, the acidic conditions gave no 
detectable changes in the reaction (Table 1, entry 1). The presence of Lewis 
acid CoCl2 or FeCl3 in MeCN (entry 2) gave only traces of the product 2.43. 
Also refluxing monoamine alcohol 2.50 with epoxide 2.41 in i-PrOH up to a 
week (entry 6) showed only traces of the desired product 2.51. On the other 
hand, in the presence of Lewis acids (metal chlorides and triflates)63 in either 
CH2Cl2 or i-PrOH gave ca 30% of 2.43 after 2–3 days at room temperature 
(entry 3). Warming the reaction to 40 °C almost doubled the yield (entry 4). 
Under microwave conditions 76% yield was achieved by irradiating the reaction 
at 110 °C for 30 minutes (entry 5).64 The tosyl-protected amino alcohol 2.44 
was converted into the product 2.45 with 80% yield by refluxing in i-PrOH for 
6 days in the presence of K2CO3 (entry 10). Other bases, like NaOMe and NaH 
yielded no detectable product (entries 7 and 8). Refluxing the tosyl-amino 
alcohol in i-PrOH in the absence of additives, did not afford the product (entry 
11) but interestingly, the benzyl-protected amino alcohols in the same 
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conditions afforded the desired products 2.47 in 74% and 2.55 in 87% yield 
(entries 12 and 13).  
 
 
Table 1. Conditions for aminolysis of epoxides. 
 
Nr R1 
amino 
alcohola epoxide product 
Reaction conditions 
yield 
addative solvent temp.b time 
1 
H 2.42 2.41 2.43 
Triflic 
acid MeCN 0 °C 24 h ncd
c 
2 Lewis acidd MeCN 82 °C 24 h traces 
3 Lewis acide 
CH2Cl2 or 
i-PrOH rt 
2–3 
days 
ca 
30% 
4 Yb(OTf)3 CH2Cl2 40 °C 2 days 57 % 
5 Bi(OTf)3 CH2Cl2 110 °Cf 30 min 76% 
6 2.50 2.51 - i-PrOH, 82 °C 7 days traces 
7 
Ts 2.44 2.41 2.45 
NaOMe MeOH rt 2 days ncdc 
8 NaH benzene 80 °C 24 h ncdc 
9 K2CO3, TBAHS DMF 100 °C 7 days 52% 
10 K2CO3 i-PrOH, 82 °C 6 days 80% 
11 2.52 2.60 2.53 - i-PrOH, 82 °C 4 days ncdc 
12 Bn 2.46 2.41 2.47 - i-PrOH 82 °C 24 h 74% 13 2.54 2.60 2.55 - i-PrOH 82 °C 48 h 87% 
14 Me 2.48 2.41 2.49 - i-PrOH 82 °C 6 days <99% 15 2.56 2.57 - i-PrOH, 82 °C 3 days 96% 
16 Ns 2.58 2.60 2.59 K2CO3 TBAH dioxane 90 °C 10 days 54% 
a For the formation of protected amino alcohols see Paper III and Experimental section 
2.4 in the thesis. 
b The reactions were run in reflux, except for entries 1, 3, 4, 5, and 7. 
c ncd – no conversion detected 
d Lewis acids CoCl2 and FeCl3 were tested. 
e Lewis acids: Sc(OTf)3, La(OTf)3, Yb(OTf)3, Bi(OTf)3, ZrCl4, ZnCl2, InCl3. 
f The reaction was run under microwave conditions. 
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The best performing nucleophiles were the methyl-protected amino alcohols 
2.48 and 2.56, with isolated yields <99% and 96% for the formed products 2.49 
and 2.57, respectively (entries 14 and 15). The nosyl-protected amino alcohol 
2.58 gave 54% of the desired product 2.59, after refluxing 10 days in dioxane 
under phase transfer conditions (entry 16). 
 
 
2.2.2.1. Deprotection strategies for N-protected amino alcohols. 
In order to incorporate the protected amino alcohol moiety into the synthesis 
route, a suitable deprotecting strategy was needed, which would not affect other 
structural units in the compound, e.g., the lactone ring. Thus, different de-
protections of N-Ts, N-Bn and N-Ns were explored. 
For detosylation three methods were explored: (1) deprotection in the 
presence of sodium naphthalene anion radical;65 (2) sonication in the presence 
of N-arenesulfonylcarbamate and magnesium turnings; 66,67 and (3) deprotection 
in the presence of samarium diiodide, triethyl amine and water, a mild reducing 
environment for deprotecting aryl sulfonate esters and amides,68 which could 
also tolerate the presence of a ,-unsaturated lactone ring.69 Although with 
test-substrates like 2.45 (Table 1) the deprotection was observed, in the 
presence of the lactone moiety a mixture of products was obtained, with either 
the lactone decomposed or the thiosulfonyl group cleaved. 
For the debenzylation two methods were tested, (1) oxidation with cerium 
(IV) ammonium nitrate (CAN), 70 and (2) hydrogenolysis with H2 and palladium 
catalyst on carbon, reported both for alcohols71  and amines. 72 . The deben-
zylation by CAN did not yield the desired product, even when the equivalence 
of CAN was increased from 1 to 2.5. The hydrogenolysis with H2 catalyzed by 
Pd occurred with high yield for the test-substrate, but when phenylsulfide 
lactone ring was also present, the catalyst was poisoned73 and no de-benzylation 
occurred.  
For denosylation a method via Meisenheimer complex, employing a thio-
compound and base was used.74 Thio-compounds, like -mercaptoethanol and 
1-decanethiol were tested in the presence of bases K2CO3 and DBU. The 
complete deprotection, indicated by 1H NMR analysis, occurred with 1-
decanethiol and DBU. When ,-unsaturated lactone ring was introduced to the 
conditions, no expected product was afforded. The reason could have been 
because of a Michael addition of the 1-decanethiol to the double bond.75 Thus, 
the denosylation reaction should be conducted before formation of the 
butenolide moiety in the structure. 
Since no suitable deprotecting methods were found for the N-Ts and N-Bn 
groups, the third best protecting group, N-Ns, for which also a good 
deprotecting method was worked out, was incorporated in the synthetic route 
for the aza-analogue with the secondary amine moiety. Also two methyl-
protected aza-analogues were to be synthesized.  
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2.2.3. Synthesis of aza-analogues A and B via AD. 
We started our synthesis with the methylated aza-analogues A and B that 
required no extra focus on N-deprotection strategies. We envisioned using the 
Sharpless’ AD method in order to introduce three stereocenters in the analogue. 
The stereocenters would be inserted one at a time and the stereochemistry 
would depend on which of the two chiral ligands was chosen. According to the 
convergent synthesis route devised, there are two main intermediates, which are 
coupled by an epoxide opening in the last stages of the route (Scheme 14). 
These intermediates are termed a left-hand fragments (here amino alcohols 2.48 
or 2.56) and a right-hand fragment (here 2.61), furnished with the lactone and 
epoxide rings. The amino alcohols were to be achieved by the method described 
above (Table 1) by opening the chiral epoxide 2.41 by an appropriate amine 
moiety. The epoxide, in turn, would be converted from a chiral diol 2.62, 
afforded after AD of commercially available 1-dodecene 2.63. The right-hand 
fragment 2.61 was to be prepared by subjecting the alkylation product of the 
iodide 2.64 and the lactone ring 2.21 to AD conditions, and converting the 
afforded diol into the epoxide in 2.61. The iodide 2.64 is a derivate of diol 2.65, 
which was to be obtained after asymmetric dihydroxylation of 1,13-tetra-
decadiene 2.35. The lactone ring 2.21 would be achieved from (phenylthio)-
acetic acid 2.66 and (S)-propyleneoxide 2.67 according to a known procedure 
by White et al.76. Due to the possibility of epimerization of the lactone ring 
under basic conditions,77 mild reaction conditions were favoured where pos-
sible, and the insertion of the double bond into the lactone ring was planned as 
one of the last steps.  
 
 
Scheme 14. Retrosynthetic scheme of acetogenin analogues A and B employing 
Sharpless’ AD of olefins. 
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Scheme 15. Synthesis of right-hand fragment 2.61 via double-AD. 
 
 
The AD of 1,13-tetradecadiene 2.35 was terminated after ca 50% conversion 
(monitored by TLC analysis) to yield diol 2.65 with er 92:878 (Scheme 15). The 
primary hydroxyl in 2.65 was regioselectively tosylated79  by p-TsCl in the 
presence of catalytic amount of Bu2SnO, and after protecting the secondary 
hydroxyl as silyl ether, the compound was converted into the iodide 2.64. Next, 
the alkylation of the lithium enolate derived from lactone 2.2180 with 2.64 was 
investigated. In an attempt to replace HMPA as an additive, which has often 
been used in similar alkylations, 81  DMPU 82  and Et3B-promoted processes 83 
were investigated but without success. We returned back to using HMPA as co-
solvent and achieved 2.68 in 78% yield by using LDA and 10 equiv. of HMPA. 
The remaining double bond was then subjected to a second Sharpless AD and 
the consequent diol 2.69 was converted into an epoxide 2.61 over tosyl-
intermediate.  
Next we had to couple the amino alcohol 2.48 with the epoxide 2.61. In the 
test reaction (Table 1, entry 10) we had achieved an excellent yield for the 
symmetrical product after almost a week in reflux. Due to the lability of the 
compound in hand, we opted for a slightly lower temperature and a shorter 
reaction time, affording 2.70 with a moderate yield of 65% (Scheme 16).  
 
 
 
Scheme 16. Synthesis of aza-analogue A. 
 
 
The double bond in the lactone ring was to be achieved by the thermal eli-
mination of phenylsulfoxide. We hoped that at low temperatures the oxidation 
of sulfide to sulfoxide would proceed selectively over nitrogen oxidation to N-
42 
oxide due to their electronic characteristics. After subjecting 2.70 to 1.1 
equivalents of m-CPBA in CH2Cl2 at –78 °C, we noticed that the tertiary amines 
were oxidized as readily as the sulfide, giving a mixture of products. Two 
options were considered – either to reduce N-oxides back to tertiary amines 
after the sulfoxide elimination, or to avoid the N-oxidation completely. A facile 
reduction of N-oxides has been reported by Gleave et al., 84  where after 
oxidation the reaction mixture was treated with 10% aqueous NaHSO4 during 
workup to recover the tertiary amine in the starting material. Unfortunately in 
the case of 2.70 an excess of the oxidation agent would be necessary to ensure 
the oxidation of all possible sites, but at the same time over-oxidation of the 
sulfide to sulfone should be avoided. This could be difficult to control and any 
over-oxidation would mean loss in the final product. Thus, we sought for an 
option to avoid the N-oxidation completely during the sulfoxide formation. A 
method to protect the tertiary amines from oxidation by forming quaternary 
amine salts85 was investigated more closely. We conducted a series of test-
reactions, where after forming the quaternary amine salt with methane sulfonic 
acid, the salt was subjected to the oxidation conditions: at –50 °C 1.1 equiv. of 
m-CPBA was added and after 20 min the reaction was quenched by 20% 
Na2S2O3 (aq.). After washing with NaHCO3 (aq. satd.), the starting material, the 
tertiary amine, was recoverable. Our investigations also showed that tempe-
rature around –20 °C was sufficient for the oxidation of sulfide to proceed and 
to avoid N-oxidation. Additionally, after the sulfoxide had formed, according to 
1H NMR analysis the elimination reaction occurred already at 60°C, which 
could make refluxing the final compound at higher temperatures (110°C in 
dioxane) redundant. It was concluded, that by converting the amine moiety to a 
corresponding quaternary ammonium salt and subjecting it to equimolar 
amounts of m-CPBA at –20 °C, the N-oxidation could be prevented during 
sulfoxide formation. The ,-unsaturated lactone derivate 2.71 was desilylated 
in acidic conditions without prior purification to yield A with 87% yield over 
the last steps. 
 
 
 
Scheme 17. Synthesis of aza-analogue B. 
 
 
The synthesis of analogue B (Scheme 17) followed identical steps as described 
for analogue A. The methylated amino alcohol 2.56 (Table 1, entry 11) opened 
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the epoxide 2.61 with a pleasingly high yield of 92% and delivered 2.72 in 
much shorter time than was needed for the corresponding diamine derivate. 
After the quaternary amine salt formation, the phenylsulfide was oxidized by m-
CPBA and the subsequent sulfoxide moiety was eliminated. The afforded 2.73 
was desilylated and the aza-analogue B was afforded with a good yield of 60% 
over the last steps. 
 
 
2.2.4. Synthesis of aza-analogues C and D via HKR 
Similarly to the previous route, there are two main intermediates, which are 
coupled in the last stages of the synthesis of the aza-analogues C and D 
(Scheme 18). Here we envisioned that the left-hand fragment (here 2.74–2.78) 
could be derived from epoxide 2.79, after it is opened by the amino- or thio-
nucleophiles. Compound 2.79 would be obtained by subjecting the racemic 
mono-epoxide 2.80 to Jacobsen’s HKR conditions. Epoxide 2.80 can be 
afforded from commercial sources or via oxidation of 1-dodecene 2.63 by m-
CPBA. The right-hand fragments 2.81 and 2.82 could be obtained by alkylating 
the lactone ring 2.21 with iodide 2.83, which is a functionalized derivative of 
the epoxy-diol 2.37. Compound 2.37, in turn, could be achieved by subjecting 
bis-epoxide 2.36 to the HKR conditions, where two remote stereocenters are set 
as shown earlier in Scheme 11. The bis-epoxide 2.36 can be obtained by 
oxidizing commercially available 1,13-tetradecadiene 2.35 with m-CPBA.  
 
 
 
Scheme 18. Retrosynthetic scheme for acetogenin analogues C-F employing Jacobsen’s 
HKR of mono- and bis-epoxides. 
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The synthesis of right-hand fragments 2.81 and 2.82 is shown in Scheme 19. 
The synthesis begun with kinetic resolution of bis-epoxide 2.36, which afforded 
epoxy-diol 2.37 and was discussed in chapter 2.2.1 (Scheme 11). The tosylate 
2.38 was prepared from epoxy-diol 2.37 as was shown in Scheme 12. After 
protecting the secondary hydroxyl in the tosylate 2.38 as a silyl ether (Scheme 
19), the compound was converted into iodide 2.83 and used for alkylating the 
lithium enolate derived from lactone 2.21. Oxidation of the sulfide moiety in 
2.81 followed by elimination, gave the ,-unsaturated lactone 2.82. It was 
noted that the elimination of phenylsulfenic acid occurred during the oxidation 
step of the sulfide moiety and for convenience these two steps were conducted 
in the same pot.  
 
 
 
Scheme 19. Right-hand fragments 2.81 and 2.82 via HKR. 
 
 
The synthesis of analogue C is detailed in Scheme 20. Due to the usefulness of 
N-nosyl protected amino alcohol as a nucleophile in epoxide opening (as show 
in Table 1, entry 16) and facile denosylation, it was employed in the synthetic 
route. The racemic epoxide 2.80 was subjected to HKR conditions with (S,S)-
(salen)Co(II) catalyst. The obtained epoxide 2.79 was subjected to 2-nitro-
benzenesulfonamide (NsNH2) at elevated temperatures over 4 days to give 
amino alcohol 2.74 in high yield. Somewhat surprisingly, coupling this material 
with epoxide 2.81 proceeded slowly, requiring 12 days to reach acceptable 
conversion. As it is difficult to remove the N-nosyl group in the presence of 
,-unsaturated lactone moiety, the protecting group had to be removed before 
the sulfide was oxidized. Thus, subjecting compound 2.84 to 1-decanethiol and 
DBU,86 yielded the secondary amine functionality in 2.85, followed by elimi-
nation, analogue C was afforded. Gratifyingly, the silyl protecting group was 
also removed in the salt formation/oxidation/elimination sequence. Analogue C 
was isolated in 63% yield over three steps. 
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Scheme 20. Synthesis of aza-analogue C. 
 
 
For the aza-analogue D two different synthetic approaches were attempted. 
Firstly, an approach similar to analogue C was followed, where a protected 
diamine moiety was introduced into the structure in order to improve the yield 
of the coupling of amino alcohol and the epoxide. A protecting group different 
from those tested in Table 1 was chosen – an N-allylamine protecting group. 
This was chosen because the allyl group, electronically similar to the Bn 
protecting group, would preform similarly well in the coupling, while allowing 
facile deprotection compatible with the other functional groups present in the 
compound. Epoxide 2.79 was opened by N,N’-diallylethylenediamine 2.86 
(Scheme 21) delivering amino alcohol 2.75 in a somewhat surprisingly low 
yield after being refluxing for 3 days. Thus, it was very pleasing when the 
coupling of 2.75 and epoxide 2.81 proceeded with a good yield of 85% at 80 °C 
just under 3 days. Deallylation of 2.87 under palladium-catalyzed conditions,87 
using Pd(PPh3)4 and N,N’-dimethylbarbituric acid (DMBA) as an allyl group 
scavenger, also proceeded in high yields. The starting material was consumed 
within one hour as indicated by TLC analysis and the product 2.88 was obtained 
in a good yield, although the difficult isolation on silica-column afforded the 
product in lower yield than was expected. Next, the final three-step procedure 
of salt formation, oxidation and elimination was performed in a similar manner 
to the other aza-analogues. The compound 2.88 was treated with 5 equiv of 
methanesulfonic acid and after 50 minutes of stirring, the solution was con-
centrated to dryness. The formed salt-protected compound was then subjected 
to 1.5 equiv of m-CPBA at -20 °C, and then after re-dissolving in toluene, to 
thermal elimination. Unfortunately the desired end-product D was not obtained 
and a mixture of unidentified compounds was isolated after the three-step 
sequence.  
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Scheme 21. An attempt to synthesize aza-analogue D by using N-allylamine protecting 
group. 
 
 
We then revisited epoxide opening with the primary amino alcohol as was 
shown in Table 1 and selected milder conditions, in the presence of Lewis 
acids, to open epoxide 2.82 with amino alcohol 2.76 (Scheme 22).23 At room 
temperature both Bi(OTf)3 and FeCl3 gave yields around 30% for the coupled 
product 2.89 (Table 2, entries 1 and 2). Using microwave conditions and 
stirring the reaction at 110 °C for 30 minutes (entry 3) gave some recovered 
starting material and unidentified byproducts. A good yield of 65% for 2.89 was 
achieved when warming the reaction at 40 °C for 2 days in the presence of 
La(OTf)3 (entry 4). After desilylation in acidic conditions, aza-product D was 
afforded (Scheme 22). 
 
 
Scheme 22. Synthesis of aza-analogue D. 
 
Table 2. Coupling of amino alcohol 2.76 and epoxide 2.82. 
 
Entry LA solvent temperature time yield 
1 Bi(OTf)3 i-PrOH  rt  3 days  39%a 
2 FeCl3 i-PrOH rt 3 days 32%a
3 Bi(OTf)3 CH2Cl2 110 °C (MW) 30 min ndb 
4 La(OTf)3 i-PrOH 40 °C  2 days 65%a
aYield of isolated product 2.89  
bnd – not determined. 
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2.2.5. Synthesis of thio-analogues E and F via HKR 
For the thio-analogues E and F a similar synthetic scheme as for aza-analogues 
C and D was followed, however, thio-fragments were used instead of amine 
fragments (Scheme 18). The epoxide 2.79 was opened by 1,2-ethanedithiol 2.90 
(Scheme 23). Different reaction conditions were explored and the best yield for 
2.77 was obtained in the presence of InCl3 in i-PrOH at room temperature.88 
Next, 2.77 was coupled with epoxide 2.82 under the same conditions, to give 
2.91. After desilylation, thio-analogue E was afforded.  
 
 
Scheme 23. Synthesis of thio-analogue E. 
 
 
The final analogue, compound F, was prepared following an identical route 
with comparable yields, except for using 2,2’-thiodiethanethiol 2.92 as the 
nucleophile (Scheme 24). Epoxide 2.79 was opened by the -hydroxy-sulfide 
2.92 with a moderate yield in the presence of InCl3. The obtained compound 
2.78 was used to open epoxide 2.82 and after desilylation, end-product F was 
obtained.  
 
 
 
Scheme 24. Synthesis of thio-analogue F. 
 
 
Several attempts were made to prepare a thio-analogue 2.94 (Scheme 25). The 
synthesis was planned according to a similar route of the previous thio-ana-
logues, where a -hydroxy-sulfide 2.95 would be coupled with epoxide 2.82.  
48 
 
 
Scheme 25. Retrosynthetic scheme for attempted thio-analogue 2.94. 
 
 
Firstly, the epoxide 2.79 was reacted with hexamethyldisilathiane [(TMS)2S], 
catalysed by tetrabutylammonium fluoride (TBAF) (Scheme 26).89 The reaction 
was monitored by TLC analysis, which showed the formation of a single 
product. Next to a TLC stain of phosphomolybdic acid solution also Ellman’s 
reagent stain90 was used. Ellman’s reagent helps to determine the presence of 
free sulfhydryl groups and is often used to determine sulfhydryl or disulphide 
groups in peptides.91 Unfortunately, based on NMR and HRMS analysis, we 
reasoned it to be the symmetric product 2.96 not the expected product 2.95. 
 
 
 
 
Scheme 26. Thiolysis of epoxide 2.79. 
 
 
Then some test reactions were conducted following a different approach: the 
racemic epoxide 2.80 was reacted with sodium hydrosulfide hydrate in MeOH 
at 0 °C (Scheme 27). The reaction proceeded sluggishly, taking two days for a 
product to form (monitored by TLC analysis). Unfortunately, the symmetrical 
product 2.97, same as 2.96, was detected with some unreacted starting material. 
Increasing the amount of NaSH from 1 equiv. to 2 equiv., only led to faster 
conversion into 2.97 and dilution of the reaction made the reaction more 
sluggish. To gain further insight of the reactivity of the epoxides and sulfides 
formed, the reaction with NaSH was repeated in the 1:1 mixture of two 
epoxides, 2.80 and propylene oxide 2.98 (Scheme 27). This gave 2.99 as a 
major product – equivalent to the symmetrical products in the previous test 
reactions. The possible formation of a disulfide bond was eliminated by sub-
jecting the thiolysis product to reductive conditions in the presence of NaBH4, 
after which only starting material was detectable.  
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Scheme 27. Thiolysis of epoxides 2.80 and 2.97. 
 
 
It was concluded that the epoxide opening by the sulfide formed through ring 
opening is more reactive compared to the ring opening by NaSH. 
A formation of a thiirane intermediate was also taken into account. To test 
this hypothesis, the reaction product was subjected to other nucleophiles, like 2-
naphthalenethiol, diethylamine, NaSH in the presence of Et3N, and benzyl-
amine, but only starting material was recovered.  
Additional approaches were explored in order to afford the -hydroxy-
sulfide 2.95 either via tosylate 92  2.101 or iodide 93  2.102 (Scheme 28), but 
unfortunately the subsequent substitution did not yield the desired compound 
2.103. 
 
 
 
Scheme 28. Attempted synthesis of intermediate 2.103. 
 
 
2.2.6. Epimerization of the lactone ring. 
The stereochemical lability of lactone ring in the acetogenins under basic con-
ditions has been described previously77 and the biological function of this 
moiety has been discussed.94,95 As the consensus has not been reached con-
cerning the effect of varying structure or the epimerization of the lactone ring 
on the bioactivity of the compound, the issue of epimerization should be 
addressed. The epimerization of the methyl moiety in the lactone ring was 
assessed by 1H and 13C NMR analysis. For some analogues, minor conta-
mination was detected in the spectra, which was attributed to diastereomers 
derived from epimerization in the lactone ring. Epimerization was detected in 
the aza-analogues A, B and C, but not seen in D or in the thio-analogues E and 
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F. We reasoned that the cause for this could be the high temperature, which was 
imposed on the first three structures during elimination of phenylsulfoxide and 
the more basic nature of the aza-analogues themselves. The analogue D was 
consecutively achieved after coupling at room temperature, as were the two 
thio-analogues E and F.  
 
 
2.2.7. Biological evaluation 
The antiproliferative activity of A-F was assessed in comparison to rotenone in 
the HeLa cell line. Rotenone is another complex I inhibitor, although claimed to 
act via different pathway. 96  The results are shown in Table 3 as the con-
centration of compound necessary to give one-half the maximum response 
(ED50). The cells were incubated with a series of dilutions of the synthesized 
analogues and of rotenone for 24 hours. The cell viability was evaluated by 
CellTiter 96®AQueous One Solution Cell Proliferation Assay. This assay uses 
tetrazolium salt TMS† that is bioreduced by cells to coloured formazan, which 
then can be measured colorimetrically. All four of the aza-analogues A-D ex-
hibited cytotoxicity under 10 M, and performed more effectively than 
rotenone (ED50 = 77.5 M). The thio-analogues E and F had less effect on cell 
growth than aza-analogues, needing concentrations around 100 M or higher to 
reach the effective dose.  
 
 
 
Table 3. Antiproliferative activity of compounds A-F in HeLa cell line.a  
  
On the Chart 1, dose-dependent antiproliferation effects are plotted as relative 
cell viability (%) against compound concentrations 0.1 M – 100 M. For 
                                                 
† TMS stands for 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)- 
2H-tetrazolium salt 
 
Entry Compound ED50 (µM) 
1 A 3.1 
2 B 7.7 
3 C 8.2 
4 D 5.7 
5 E 91.0 
6 F  > 100 
7 Rotenoneb 77.5 
 
a HeLa cell line, human epitheloid cervix  
carcinoma.  
b Rotenone, as a known complex I inhibitor, was  
used as a positive control. 
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compounds A-E concentration 5 M is added to illustrate the steepness of the 
cytotoxicity curve. This was omitted for F and rotenone, which followed a 
shallower slope, suggesting lower potency. The best result was achieved by the 
N,N’-dimethylated diamine analogue A, which at the concentration 3 M had a 
cytotoxicity on 34.7  4.4% of cells, while at 5 M on 91.93.3% of cells (ED50 
= 3.1 M). Based on our findings, the epimerization of the butenolide in A did 
not seem to have a great effect on the bioactivity as the antiproliferative activity 
of A falls in the same range with its non-methylated counterpart D (ED50 =  
5.7 M), where epimerization was not detected. The N-methylated analogue B 
and the non-methylated analogue C had similar effective doses of 7.7 M and 
8.2 M, respectively. It seems that the diamine containing aza-analogues, 
whether methylated or not, are more cytotoxic than their monoamine counter-
parts.  
 
 
Chart 1. Dose-dependent effects of analogues A–F and rotenone on cell viability in 
HeLa cell line. The relative cell viability, represented as percentage, was determined by 
MTS assay at 24 hours after treatment. 
 
 
Many of the in vitro studies have been conducted over lengthier period of time, 
around 2 to 7 days. It has been shown that both the natural acetogenins 
(bullatacin)97 and the polyether-analogue98 effect the proliferation of cells also 
in time-dependent manner. We made a survey of dose-dependent cytotoxicity 
by incubating the cells over 24 h with different concentrations of our analogues 
synthesized. Although the incubation time interval was much shorter compared 
with the literature, a good dose-dependent curve was observable with the aza-
analogues synthesized.   
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2.3. Conclusions 
Four aza-analogues A–D and two thio-analogues E and F were synthesized 
according to the convergent synthetic scheme, which allows facile variability in 
the central part of the molecule containing heteroatoms. When there are 
examples of nitrogen containing analogues, the thio-analogues of acetogenins 
have not been reported to our knowledge. Two approaches to set the stereo-
chemistry were compared – Sharpless asymmetric dihydroxylation of olefins 
and hydrolytic kinetic resolution of epoxides using the Jacobsen’s catalyst. The 
best results in obtaining a crucial intermediate were achieved by the hydrolytic 
kinetic resolution of bis-epoxides. This useful and easily operative method 
established two remote stereocenters with high enantio- and diastereoselecti-
vity, and allowed further two directional derivatization of the intermediate 
towards the end product. All the analogues synthesized underwent preliminary 
in vitro studies in the HeLa cell line. Aza-analogues showed 50% cell viability 
reduction at concentrations under 10 M, while thio-analogues had less effect, 
needing concentrations around 100 M and above to reach effective dose. 
Although we observed epimerization in the butenolide for aza-analogues A–C, 
the bioassay studies did not reflect significant activity differences between 
analogues A–C and the non-epimerized analogue D. To gain more under-
standing about the cytotoxicity of our synthesized analogues, different tumorous 
cell lines next to normal cell tissues have to be assessed with the compounds. 
Also, a more effective positive control would be useful. 
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2.4. Experimental 
Compound 2.44 
 
 
 
Epoxide 2.41 (369 mg, 2.00 mmol), TEBA (46 mg, 0.20 mmol), K2CO3  
(28 mg, 0.20 mmol) and N,N’-bis(4-methylbenzenesulfonyl)ethane-1,2-diamine  
(1474 mg, 4.00 mmol) were dissolved in dioxane (3 mL) and stirred at 90 °C 
for 27 h. The crude was purified by column chromatography on silica (1.5% 
MeOH in CHCl3). The product 2.44 was obtained as amorphous solid (870 mg, 
79% yield). Rf = 0.5 (5% MeOH in CHCl3). 1H NMR (400.1 MHz, CDCl3) δ: 
7.75 (m, 2H), 7.63 (m, 2H,) 7.32–7.28 (m, 4H), 6.03 (m, 1H), 3.88–3.81 (m, 
1H), 3.38–3.30 (m, 1H), 3.28–3.15 (m, 2H), 3.13–3.07 (m, 1H), 3.08 (dd, 
J=14.7, 2.8 Hz, 1H), 2.88 (dd, J=14.7, 9.5 Hz, 1H), 2.42 (s, 6H), 1.44–1.22 (m, 
18H), 0.90 (vt, 3H). 13C NMR (50.3 MHz, CDCl3) δ: 143.9, 143.3, 136.9, 134.9, 
129.9, 129.7, 127.3, 127.1, 71.0, 56.9, 50.9, 43.3, 35.0, 31.9, 29.58, 29.56, 
29.55, 29.52, 29.3, 25.3, 22.7, 21.5, 14.1. 
 
 
Compound 2.75 
 
 
 
A solution of epoxide 2.79 (505 mg, 2.74 mmol) and N,N'-bis(prop-2-en-1-
yl)ethane-1,2-diamine 2.86 (1050 mg, 7.49 mmol) in i-PrOH (1.0 mL) was 
heated at 100 °C for 73 h. The excess of the unreacted diamine was distilled off 
under vacuum (ca 150 °C, 0.22 mbar) and the crude containing the product was 
purified by flash chromatography on silica (5–15% MeOH in CH2Cl2). The 
product 2.75 was obtained as amorphous solid (311 mg, yield 35%). Rf =0.4 
(10% MeOH in CH2Cl2). 1H NMR (400.1 MHz, CDCl3) δ: 5.95–5.84 (m, 1H); 
5.88–5.77 (m, 1H); 5.20–5.07 (m, 4H); 3.63–3.56 (m, 1H); 3.28–3.21 (m, 3H); 
3.07 (dddd, J=14.2, 7.4, 1.1, 1.1 Hz, 1H); 2.84 (bs, 2H); 2.78–2.64 (m, 3H); 
2.58–2.49 (m, 1H); 2.46 (dd, J=13.0, 2.9 Hz, 1H); 2.32 (dd, J=13.0, 10.1 Hz, 
1H); 1.49–1.21 (m, 18H); 0.87 (vt, 3H). 13C NMR (50.3 MHz, CDCl3) δ: 136.5, 
135.3, 117.8, 116.2, 68.1, 60.5, 58.3, 53.6, 52.1, 46.9, 34.8, 31.9, 29.8, 29.6, 
29.3, 25.7, 22.7, 14.1. 
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Compound 2.87 
Solution of allyldiamine 2.75 (39 mg, 0.121 mmol) and epoxide 2.81 (66 mg, 
0.121 mmol) in i-PrOH (0.5 mL) was stirred at 80 °C for 68 h for ca 2.5 days. 
The course of the reaction was monitored by TLC analysis. Then the mixture 
was concentrated to dryness and purified by column chromatography on silica 
(1 % MeOH in CH2Cl2) obtaining product 2.87 as a beige oil (90 mg, yield  
85 %). 1H NMR (400.1 MHz, CDCl3), : 7.58–7.50 (m, 2H); 7.42–7.29 (m, 
3H); 5.92–5.79 (m, 2H); 5.22–5.10 (m, 4H); 4.59 (m, 0.38H, minor isomer); 
4.51 (m, 1H, major isomer); 4.24 (m, 1H); 3.70–3.57 (m, 2H); 3.30–3.16 (dd, J 
= 13.9 Hz, 2H); 3.17–2.98 (dd, J = 13.9 Hz; dd, J = 14 Hz; 3H); 2.73–2.61 (m, 
2H); 2.57–2.26 (m, 7H); 2.39–2.26 (m, 2H); 2.10–1.78 (m, 2H); 1.50–1.34 (m, 
8H); 1.34–1.07 (m, 47 H); 0.89 (bs, 9H); 0.86 (vt, bs of minor isomer, 6H);  
0.15 (bs, 3H); 0.11 (bs, 3H); 0.03 (bs, minor), 0.02 (bs, minor). 13C NMR  
(100.6 MHz, CDCl3), : 177.4 (major isomer); 175.0 (minor isomer); 136.9; 
136.9 (minor); 136.6 (major); 134.8 (bs); 130.4 (major); 130.4 (minor); 129.8; 
129.6 (minor); 129.5; 128.9; 128.8 (minor); 118.1 (bs); 73.5 (minor); 73.2 
(major); 70.2 (minor); 69.5; 68.4; 61.1; 58.0; 55.3; 55.3 (minor); 52.9 (bs); 42.4 
(minor); 41.6 (minor); 41.2 (major); 39.5; 38.5; 37.9 (minor); 34.7; 34.2 
(minor); 31.8; 29.8–29.3 (overlapping signals); 29.2; 25.9; 25.9; 25.7; 25.7; 
24.4; 24.4; 22.6; 21.2 (overlapping with minor peak); 20.3 (minor); 17.9; 14.0: -
3.7 (minor); -3.8; -4.1 (minor). IR (cm-1) max: 3429.5; 2924.0; 2854.6; 1766.8; 
1462.0; 1184.2; 1053.1; 1002.9; 918.1; 833.2; 775.3. HRMS (m/z) calcd for 
C51H92N2O5SSi (M+H)+ 873.6569, found 873.6552. 
 
 
 
 
Compound 2.88 
To a solution of N,N’-dimethylbarbituric acid (DMBA) (46 mg, 0.297 mmol) 
and Pd(PPh3)4 (1.6 mg, 1.38 μmol) in CH2Cl2 (0.2 mL) was added allylamine 
2.87 (43 mg, 49.5 μmol) in CH2Cl2 (0.5 mL) and stirred at 35 °C for 1 h under 
argon atmosphere. Then the mixture was concentrated to dryness and re-
dissolved in Et2O. The solution was washed two times with small volumes of 
Na2CO3 (aq. satd.) and 2 N HCl until white precipitation formed in the organic 
phase. The organic phase was filtrated to remove solids. The filtrate was 
concentrated in vacuo and purified by column chromatography on silica (10 % 
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MeOH in CH2Cl2) obtaining product 2.88 as a beige oil (27 mg, yield 68 %). 1H 
NMR (400.1 MHz, CDCl3), : 7.58–7.51 (m, 2H); 7.43–7.30 (m, 3H); 4.59 (m, 
0.3H, minor isomer); 4.51 (m, 1H, major isomer); 4.48 (bs, 1H); 4.25 (m, 1H); 
4.00–3.88 (m, 2H); 3.37–3.08 (bs, 3H); 3.05 (dd, 1H); 2.97–2.73 (m, 4H); 2.48–
2.26; 2.11–1.79 (m, 4H); 1.54–1.35 (m, 10H); 1.35–1.11 (m, 50 H); 0.89 (bs, 
9H); 0.86 (vt, bs of minor isomer, 7H); 0.15 (bs, 2.3 H); 0.11 (bs, 2.5 H); 0.03 
(minor); 0.02 (minor). 13C NMR (100.6 MHz, CDCl3), : 177.5 (major isomer); 
175.1 (minor isomer); 137.0; 136.6; 130.4; 129.9 (minor); 129.6 (minor); 129.5; 
128.9 (major); 128.9 (minor); 73.6 (minor); 73.3 (major); 70.2 (minor); 69.5 
(major); 55.5 (major); 55.1 (minor); 54.0 (minor); 42.4 (minor); 41.7 (minor); 
41.2 (major); 39.5; 38.5; 38.0 (minor); 35.1 (decayed); 31.9; 31.4 (minor); 30.1 
(minor); 29.8–29.4 (overlapping signals); 29.3; 26.0 (overlapping signals); 25.5; 
24.4; 22.6: 21.3: 20.3; 18.0; 14.1; -3.7 (minor); -3.8 (major); -4.1 (minor). IR 
(cm-1) max: 3336.8; 3232.7; 2924.0; 2850.7; 1766.8; 1462.0; 1438.9; 1253.7; 
1184.2; 833.2; 775.3. HRMS (m/z) calcd for C45H84N2O5SSi (M+H)+ 793.5943, 
found 793.5937. 
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3. ASYMMETRIC TRANSFER HYDROGENATION 
COUPLED WITH 
DYNAMIC KINETIC RESOLUTION OF 
-AMIDO--KETO ESTERS 
(Paper IV and V) 
 
3.1. Introduction 
Derivatives of -hydroxy--amino acids are important structural units that can 
be found in many complex bioactive compounds. For example, this unit can be 
found in papuamides A and B99  (Scheme 29), and also in kaitocephalin100 
(Scheme 30), a relatively simple natural product compared to the afore-
mentioned. Papuamide is a natural product with a strong inhibitory effect on the 
infection of human T-lymphoblastoid cells by HIV-1. The synthesis of the anti 
amino alcohol structure unit 3.1 found in its core (shaded in gray in Scheme 29) 
was achieved by Xie et al. by oxidizing the alcohol in L-serine derivate 3.2 into 
an aldehyde and a subsequent Grignard reaction.101  
 
Scheme 29. Papuamide A and B 
 
 
Kaitocephalin (Scheme 30) has become a promising lead compound towards 
therapeutic agents against various neuronal diseases, and thus its synthesis has 
gained a lot of attention over the years. For example, an 11 step synthetic route 
was developed by Chamberlin and co-workers using a C-acylation of a 
pyrrolidine ester 3.3 with N-acylimidazole 3.4 giving a single diastereomer of 
3.5,102 and after treating with DIBALH the reduced product was afforded with 
dr > 30:1 (Scheme 30, a). This effort needed several tries and steps to reach the 
desired compound. Also, Sharpless asymmetric epoxidation of 3.6 and a sub-
sequent opening by azide anion have been employed towards the end product 
(b),103 and also rhodium-catalyzed allylic C-H amination on the cyclopentene 
ring of 3.7 and a subsequent oxidative cleavage of the double bond in the cyclic 
carbamate (c). 104  The examples provide the C-2 and C-3 stereocenters in 
 
 
H
N N
O
O
R OH
NH O NHO
NHMeO
O
HN
O
O
N
O
OMe
OH
O
O
NH2
HN
O
HN
H2N
O
OHH
N
O
N
H
O
HO
OH
papuamide A, R = Me
papuamide B, R = H
AllylO O
NHBoc
N
HO O
THPO OH
NBn2
3.1 3.2
R1 OR3
OH
NHR2
O
* *
!"hydroxy"#-amino acid
derivative
62 
individual steps, but by employing ATH both stereogenic centers could be 
achieved simultaneously. 
 
 
 
Scheme 30. Selected synthetic approaches towards (–)-kaitocephalin. 
 
 
3.1.1. Synthesis of -hydroxy--amino acid derivates 
Many elegant methods have been reported for the synthesis of -hydroxy--
amino acid derivates, e.g., aldol reaction, Sharpless asymmetric epoxidation,  
-dihydroxylation or -amination, Strecker reaction, and many others (Scheme 
31).105  
  
 
 
Scheme 31. A selection of methods for the synthesis of -hydroxy--amino acid 
derivates. 
 
 
There have also been many attempts towards establishing a general and 
efficient method to achieve high stereoselectivity for both alkyl- and aryl sub-
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strates. For example, Feng and co-workers reported the catalytic asymmetric 
aldol reaction in order to achieve the -hydroxy--amino acid derivatives with 
anti-selectivity (Scheme 32).106 They treated -isothiocyanato imide 3.8 with 
aldehyde 3.9 (or any appropriate aldehyde depending on the end product) in the 
presence of a ligand-[Ni(acac)2] complex (2.5 mol%) and achieved 3.10 with 
high stereoselectivity and yield. After reduction of 3.11, the product 3.12 was 
afforded. These air-tolerant conditions were found to be compatible with a 
scope of aryl- and alkyl-substrates giving good to excellent enantio- and 
diastereoselectivities.  
 
 
Scheme 32. Synthesis of -hydroxy--amino acid derivatives via aldol reaction. 
 
 
Amador et al. on the other hand, proposed a route according to which products 
with both anti- and syn-configuration could be achieved (Scheme 33), although 
this was demonstrated only on alkyl substrates. 107  They started with sym-
metrical alkyne diol 3.13, which was transformed to corresponding (E)-diol 
3.14 or (Z)-diol 3.18 by selective reductions. After Pd(0)-catalyzed allylic 
alkylation of 3.15 and 3.19, the corresponding  carbamates of the diols, oxazoli-
dinines 3.16 and 3.20, were formed with dr >95:5. These could be further 
elaborated to the corresponding amino acids 3.17 and 3.21. 
 
 
 
Scheme 33. Synthesis of alkyl -hydroxy--amino acids with anti- and syn-configu-
ration from (E)- or (Z)-diols. 
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Another interesting example is the route via Strecker reaction (Scheme 34), 
which was shown to work both with alkyl and aryl substrates and also towards 
both syn- or anti-selectivity.105h The -substituted aldehyde 3.22 was treated 
with (S)-p-toluene-sulfinamide in the presence of 6 equiv. of Ti(OEt)4, and the 
corresponding sulfinimine 3.23 was in turn treated with ethylaluminium 
cyanoisopropoxide generated in situ from i-PrOH and Et2AlCN. The authors 
reasoned that the sulfinyl group directed the addition of the CN-group from the 
Re-face, giving rise to the compound 3.24. After refluxing in 3 N HCl, anti-3.25 
was afforded with >95% ee. No diastereomers were detected by NMR analysis. 
 
 
 
Scheme 34. Synthesis of an amino alcohol with an anti-selectivity via Strecker reaction. 
 
 
In this light, asymmetric transfer hydrogenation via dynamic stereomutation or 
dynamic kinetic resolution is a relatively new approach towards the -hydroxy-
-amino acids and has a great advantage of setting the two adjacent stereo-
centers in one transformation. 
 
 
3.1.2. ATH and AH via DKR 
Reductions by asymmetric hydrogenation (AH) and asymmetric transfer 
hydrogenation (ATH) produce products in high stereoselectivities and yields.108 
In AH molecular hydrogen, and in ATH a hydrogen donor is used in the 
reduction process. There is tendency towards ATH becoming a good alternative 
to AH, which would eliminate the need for high pressures and the use of 
hydrogen gas.  
The first AH of α-substituted β-keto esters via DKR in the presence of a 
ruthenium catalyst and a chiral ligand was reported by Noyori et al. as a good 
method to achieve the product in high enantioselectivity and yield. 109   By 
subjecting substrates that possess a chirally labile stereogenic center prone to 
racemization during the hydrogenation reaction, DKR can afford a single 
enantiomer in up to 100% yield (Scheme 35).110 For example, β-keto esters with 
-amino groups. 
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Scheme 35. Enantioselective hydrogenation of α-amino-β-keto esters via DKR. 
 
 
Noyori showed that the reduction of 3.26, 3.28 (Scheme 36) and other similar N-
protected -amino--keto esters, afforded the reduced products with a high ee 
and a syn-selectivity. These results were soon confirmed by other research 
groups, e.g. Mohar et al., who studied similar substrates as Noyori but instead of 
AH, subjected them to ATH via DKR with equally good results.111 Product 3.30 
was also one of the first ATH of -amino--keto esters via DKR reported. The 
respective anti-product had to be achieved with other methods, often needing 
additional steps. By then Noyori had already demonstrated ATH on aromatic 
ketones in i-PrOH,112 although the reduced products were achieved with lower 
ee’s compared to the AH method. In 2004 Hamada and co-workers113 showed 
that using the conventional AH conditions, a product 3.33 with anti-selection was 
achievable with high ee and dr. They claimed that an amine hydrochloride salt led 
to the opposite selectivity and the reaction proceeded via five membered 
transition state (TS) resulting in the anti-product (Scheme 37).  
 
 
 
Scheme 36. AH and ATH of amino keto esters. 
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At this time, Genêt and co-workers had also accessed the anti--amino--
hydroxy esters using the unprotected amines,114 and suggested the preference 
towards the anti-configuration arises from the chair-like TS, where the 
NH2HCl group would be in the equatorial position.  
 
 
 
 
Scheme 37. Transition states (TS) suggested by Hamada and Genêt for syn- and anti 
selectivity ( P P, BINAP).  
 
 
A question whether the reduction of keto esters takes place via ketone reduction 
or enol reduction has also been under study (Scheme 38). Noyori109 showed by 
the isotope labeling experiment that the anti-selection is achieved via ketone 
reduction. They subjected 3.34 to AH conditions. If the deuterated substrate 
would proceed via enolization, it would loose the -deuterium. But the product 
3.35 was afforded with 80% of the deuterium retained in the -position and had 
no deuterium at -position. Hamada and co-workers demonstrated also with the 
help of isotopic labeling, that the reduction of a hydrochloride salt of an -
amino--keto ester 3.36 proceeds via enol form under the same conditions and 
gives rise to the anti-selectivity in product 3.37.115 
 
 
 
 
Scheme 38. Ketone reduction and enol reduction. 
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Noyori proposed that when using the diamine or β-amino alcohol ligands with 
the Ru(arene) complexes, the transfer hydrogenation proceeds via a six-
membered pericyclic TS structure (TS1, Figure 11) rather than TS2, where the 
metal coordinates directly to carbonyl oxygen.116 The hypothesis was based on 
calculations in a gas phase and the six atoms in TS were thought to locate 
almost in one plane. The favored TS for aryl substrates may arise from the 
stabilization interaction of C(sp2)H/ between the Ru(arene) complex and the 
aryl substituent of the substrate due to the increased -donation of arene.117  
 
 
 
 
Figure 11. Metal-ligand bifunctional catalysis. Enantiodifferentiation of aryl substrates. 
 
 
Noyori’s ruthenium-ligand bifunctional complexes have found recognition, 
although recent calculations have suggested more complex mechanism, and a 
probable involvement of two catalytic cycles.118  
 
 
3.2. Results and discussion 
3.2.1. ATH via DKR using triethylformiate as hydrogen donor 
This project grew out of a topic concerning the synthesis of -hydroxy--amino 
acid derivatives using addition of azomethine ylides to aldehydes.119 In order to 
prepare the -hydroxy--amino acid derivatives with syn-configuration in 
higher stereoselectivity that was achieved by the method under study, additional 
ones, like AH and ATH were explored. ATH via DKR provided results worth 
further studies. There are many chiral ligands reported to accompany the metal 
complexes for reductions.120 At first an array of known ligands, including (S,S)-
BnDPAE, (S,S)-TsDPEN and (S,S)-pseudoephedrine were tested with two 
ruthenium complexes – [RuCl2(p-cymene)]2 and [RuCl2(benzene)]2 in reducing 
ketone 3.39a (Scheme 39). This is discussed in more length in Paper IV. The 
best results based on stereoselectivity and yield were achieved with the ligand 
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(S,S)-BnDPAE and [RuCl2(benzene)]2, which were also chosen for the fol-
lowing studies. Initially syn-selectivity was expected for 3.40a, as was reported 
in the literature for 3.42 after reducing a similar compound 3.41,121 but some-
what surprisingly anti-selectivity was achieved for 3.40a.§ 
 
 
 
 
Scheme 39. Product 4.40a with anti-configuration was achieved after subjecting 3.39a 
to ATH via DKR. Substrate 3.41 from literature had given a syn-product 4.42 under 
similar conditions. Reaction conditions using combinations of chiral ligands and ruthe-
nium complexes were explored.  
 
 
Intrigued with the results afforded for 3.40a a scope of aromatic substrates was 
planned to test the found conditions on. This constituted of substrates where the 
benzyl ring was furnished with either EWG or EDG, and also a naphthyl- and a 
thienyl-substrate. Both EDG, like ortho-positioned metoxy in 3.39b (Table 4, 
entry 2) and bromo substrates (entries 3–5) gave high yields and excellent 
enantioselectivities, also the para-fluoro substrate 3.39f (entry 6). Surprisingly 
the meta-chloro substrate afforded a lower yield with a rather disappointingly 
low stereoselectivity (entry 7). The substrate 3.39h and a naphthyl substrate 
3.39i both gave excellent yields and enantioselectivities (entries 8 and 9). 
Unfortunately the thienyl-substrate afforded lower selectivities as well. 
 
  
                                                 
§ The general procedure for the reduction reaction was as follows: the ruthenium-ligand 
complex was formed by heating [(RuCl2(benzene)]2 and the ligand (S,S)-BnDPAE at 80 °C 
for 1 hour in i-PrOH. After cooling to room temperature, the catalyst was added to the 
substrate and the reaction was stirred at room temperature in HCOOH-Et3N (5:2) mixture 
until the consumption of the starting material. 
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Table 4. ATH or aryl substrates using triethylammonium formate as a H-donor.a 
 
 
Alongside the azeotropic mixture of HCOOH:Et3N, i-PrOH can be a hydrogen 
donor in the transfer hydrogenation reaction. To be certain that in our con-
ditions the hydrogen does not originate from the i-PrOH used in catalyst 
formation, but from the formate, a test reaction was run where using the same 
reaction conditions, but excluding the formate. This reaction was run over night 
at room temperature. However, no conversion to the product was detected and 
only the starting material was visible while monitoring by TLC analysis.  
 
 
3.2.2. ATH via DKR in emulsions using  
sodium formate as hydrogen donor 
Keen on widening the scope and improving the reaction conditions we explored 
this reaction further. Encouraging results had also been achieved by conducting 
 
 
entry Product 3.40a-j yield (%)
b drc erd 
1 a 95 >95:5 97:3 
2 b 83 >95:5 99:1 
3 c 76 >95:5 99:1 
4 d 94 >95:5 96:4 
5 e 81 >95:5 98:2 
6 f 89 >95:5 96:4 
7 g 69 >95:5 66:34 
8 h 95 >95:5 97:3 
9 i 93 >95:5 95:5 
10 j 75 80:20  76:24 
 
a General reaction conditions: the solution of [RuCl2(benzene)]2 (0.1 equiv.) and (S,S)-
BnDPAE (0.2 equiv.) in i-PrOH (c = 0.1 M) at 80 °C for 1h. After cooling to rt, the 
catalyst was added to the substrate 3.39 (1.0 equiv.) with HCOOH:Et3N complex 5:2  
(c = 0.2 M). The reaction was stirred for 5–7 days at rt.  
b Isolated yield of product. 
c Determined by 1H NMR. For >95:5 only one isomer was visible. 
d Determined by chiral HPLC. 
MeO
MeO
OR2
O O
NHBoc
(S,S)-BnDPAE
[RuCl2(benzene)]2
HCOOH:Et3N (5:2)
OR2
OH O
NHBoc
R1
S
a R1= H, R2= Me
b R1= 2-OMe, R2= Et
c R1= 2-Br, R2= Et
d R1= 3-Br, R2= Et
e R1= 4-Br, R2= Et
f R1= 4-F, R2= Et
g R1= 3-Cl, R2= Et
h R2= Et
i R2= Et
j R2= Et
3.40a-j3.39a-j
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hydrogenations in water medium.122  The reduction of ketones in water had 
shown increased reaction rates accompanied by excellent enantioselectivities 
compared to the azeotrope mixture as the reaction medium.123 Thus, we were 
curious to study the aqueous conditions to see if we could shorten the reaction 
times for our substrates. Water as a solvent is a matter worth exploring because 
it possesses many good properties – it is generally non-hazardous, environ-
mentally friendly and easily accessible, and also in many cases, acts as a 
reagent or an accelerator in the reaction.124 To overcome problems with solubi-
lity a suitable surfactant can be added for some water insoluble organic com-
pounds or the use of emulsions. Instead of TEAF, sodium formate can also be 
used as a hydrogen donor, especially in aqueous media. Unfortunately when 
submitting 3.39a to sodium formate and water conditions with Ru-complex and 
either ligands BnDPAE or TsDPEN did not result the conversion of the starting 
material. Instead the aggregation of reagents was observed. By adding i-PrOH 
as a co-solvent, the reaction did result in the formation of the product, but with 
lower yield and stereoselectivity (Scheme 40).   
 
 
 
Scheme 40. ATH in i-PrOH/H2O conditions. 
 
 
During that time a new approach in ATH appeared by Wang et al., where ATH 
of ketones was conducted in CH2Cl2-water emulsions. 125  We subjected the 
substrate 3.39a in the presence of [RuCl2(benzene)]2 and ligand (S,S)-BnDPAE 
to the reported emulsion conditions (Table 5, entry 1). The product 3.40a was 
isolated with a same excellent yield as in the case of using TEAF, and in high 
stereoselectivity in much more shorter time but unfortunately with slightly 
lower diastereoselectivity (Table 5, entry 1). In the search to improve the dia-
stereoselectivity, we lowered the pH of the reaction from 7 to 5. It had been 
reported that transfer hydrogenation of ketones in aqueous conditions in the 
presence of Ru-catalyst could be pH dependent and prefer more acidic 
environment.126 It was claimed that not only did the acidic media stabilize the 
catalyst employed but also controlled the reaction by activating the ketones 
through protonation, which is dependent on the Lewis acidity of the carbonyl 
carbon that accepts the hydride from the catalyst. But close to no conversion of 
the starting material 3.39a was observed at pH 5 (entry 2). After running the 
ATH in basic conditions by adding 5 equivalents of Et3N, essentially raising the 
pH to ca 9, product 3.40a was afforded in a good yield, but with similar low dr 
as for reaction run in environment with pH 7 (compare entries 1 and 3). This is 
consistent with another reports that claim a loss of ATH reaction rate at low 
pH.127 We then cooled the reaction down and run the hydrogenation at -5 °C 
(entry 4), which did increase the reaction times to 2–3 days, but pleasingly also 
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increased the dr – only one diastereomer was detectable and a high er of 97:3 
was retained. 
 
Table 5. Optimization of ATH conditions in emulsion for 3.39a.a 
 
  
entry pH t (°C) yield (%)b drc erd 
1 pH 7 rt 97 92:8 96:4 
2 pH 5 rt traces - - 
3 pH 9e rt 95 92:8 n.d. 
4 pH 7 -5 °C 92 >95:5 97:3 
 
aGeneral reaction conditions: the solution of [RuCl2(benzene)]2 (5 mol %), (S,S)-
BnDPAE (1 mol %) and Et3N (2 mol %)in CH2Cl2 (c = 0.1 M) was stirred at 40 °C for 
1h. After cooling to rt, the catalyst was added to the substrate 3.39a (1.0 equiv.) along 
5M HCO2Na (aq.) and TBAI. The mixture was sonicated for 5–10 min and then stirred 
at rt over night.  
bIsolated yield of product. 
cDetermined by 1H NMR. For >95:5 only one isomer was visible. 
dDetermined by chiral HPLC. 
e5 equiv. of Et3N was used 
 
These new reaction conditions were tested against the substrate scope (Table 6). 
Selected aryl substrates from the TEAF scope were subjected to the emulsion 
conditions and the reaction was run either at room temperature or at –5 °C. 
After 3.39a (Table 6, entry 1), 3.39b with electron donating group ortho-MeO 
gave comparable results in emulsion with TEAF conditions even at room 
temperature while shortening the reaction time to ca 16 h (entry 2). But 3.39f 
furnished with para-fluoro had to be cooled to –5 °C to increase stereo-
selectivity (compare entries 3 and 4). Cooling prolonged the reaction time to 2–
3 days, while at room temperature almost full conversion could be achieved 
over night although in slightly lower dr. Gratifyingly, 3.39g also gave good 
results in the –5 °C emulsion, the same meta-chloro substrate that gave modest 
results with the TEAF method (compare Table 6, entry 5 with Table 4, entry 7). 
And both the naphthalene substrate 3.39i and thiol-derivate 3.39j afforded 
excellent enantio- and diastereoselectivities at –5 °C (entries 6 and 8). Satisfied 
with the results for aryl substrates we ventured to test the conditions on the 
alkyl amino keto esters. To facilitate the analysis of the alkyl products, we 
introduced Cbz-protecting group instead of Boc, which for the substrate 3.39k 
gave slightly lower selectivity (entry 9). 
Nevertheless, alkenyl substrate 3.39l and tert-butyl substrate 3.39m afforded 
equally good selectivities and yields as for the aryl substrates (entries 10 and 
11), although the latter needed longer time to reach near full conversion (ca 7 
days). Interestingly, c-hexyl substrate 3.39n and ethyl substrate 3.39o did not 
preform well under the same conditions, affording low selectivities (entries 12 
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and 14). When running the reduction in a different catalyst system, with the 
metal complex [RuCl2(p-cymene)]2 and ligand (S,S)-TsDPEN, both substrates 
delivered excellent results (entries 13 and 15). 
 
Table 6. ATH of aryl and alkyl substrates in emulsion conditions.a 
 
 
 
entry Product 3.40a-o Pg t (°C) yield (%)
b drc erd 
1 a Boc -5 92 >95:5 97:3 
2 b Boc rt 88 94:6 97:3 
3 f Boc rt 83 92:8 96:4 
4 f Boc -5 85 >95:5 98:2 
5 g Boc rt 85 94:6 96:4 
6 i Boc -5 87 >95:5 96:4 
7 j Boc rt 79 86:14 88:12 
8 j Boc -5 86 91:9 95:5 
9 k Cbz -5 86 >95:5 89:11 
10 l Cbz -5 90 95:5 97:3 
11 m Cbz -5 95 >95:5 99:1e 
12 n Cbz -5 93 60:40 n.d. 
13f n Cbz -5 92 95:5 97:3 
14 o Cbz -5 72 67:33 n.d. 
15f o Cbz -5 97 92:8 94:6 
aGeneral reaction conditions: the solution of [RuCl2(benzene)]2 (5 mol %), (S,S)-
BnDPAE (1 mol %) and Et3N (2 mol %) in CH2Cl2 (c = 0.2 M) was stirred at 40 °C for 
1h. After cooling to rt, the prepared catalyst was added to the substrate 3.39 (1.0 equiv.) 
OR2
O O
NHPg
(S,S)-BnDPAE
[RuCl2(benzene)]2
NaO2CH, TBAI
H2O, CH2Cl2
OR2
OH O
NHPg
R1
S
i R2= Et
j R2= Et
a R1= H, R2= Me, Pg = Boc
b R1= 2-OMe, R2= Et
f R1= 4-F, R2= Et
g R1= 3-Cl, R2= Et
k R1= H, R2= Me, Pg = Cbz
l R2= Me
m R2= Me
n R2= Et
o R2= Me
3.39a-o 3.40a-o
along with 5M HCO2Na (aq.) and TBAI. The mixture was sonicated for 5–10 min at 0 
°C and then stirred over night at room temperature or 2–3 days at –5 °C. 
bIsolated yield of product. 
cDetermined by 1H NMR. For >95:5 only one isomer was visible. 
dDetermined by chiral HPLC.  
eDetermined by Mosher ester analysis. 
f[RuCl2(p-cymene)]2 (5 mol %) and (S,S)-TsDPEN (10 mol %) was used. 
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It is worth noting, that when the tert-butyl and c-hexyl substrates were fur-
nished with the Boc-group instead of Cbz-group, as in 3.39r and 3.39s (Figure 
12) and subjected to emulsion conditions, the products were afforded in much 
lower yields and diastereoselectivities and thus were not studied further.  
  
Figure 12. Additional substrates for ATH in emulsions. 
 
Cinnamic derivates, e.g. ceramide128 and sphingosine129 derivates and are often 
used in the synthesis of bioactive compounds. Thus, the substrate 3.39p was 
also subjected to emulsion conditions (Scheme 41). Disappointingly, a mixture 
of products was afforded, a similar result also occurred under the TEAF 
conditions. Although the major product was identified as the reduced product 
3.40p, also products 3.42 and 3.43 formed, with reduced double bond.  
 
Scheme 41. Cinnamic substrate 3.39p gave a mixture of products under ATH emulsion 
conditions.  
 
3.2.3. Determination of relative stereochemistry of ATH products. 
The relative stereochemistry of selected ATH products was determined via 
transformation into known oxazolidinones and assessing the vicinal proton J 
coupling by 1H NMR. The phenyl substrate 3.40a was turned into oxazoli-
dinone 3.44a in the presence of triphosgene after deprotection of the Boc-amine 
in acidic conditions (Scheme 42). The JHH = 9.0 Hz value indicates a cis-
oxazolidinone, which in turn corresponds to the anti configuration of 3.40a. The 
acquired data also matches that reported for the identical oxazolidionone.130 
Although the absolute stereochemistry of 3.40a was not determined, the optical 
rotation of 3.40a matched the data for the same compound reported in the litera-
ture.131  
 
Scheme 42. Oxazolidinone 3.44a 
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Similar steps were taken to confirm the relative stereochemistry of the alkyl 
compounds 3.40m and 3.40o (Scheme 43). The JHH = 6.2 Hz for tert-butyl oxa-
zolidinone 3.44m and JHH = 8.3 Hz for ethyl oxazolidinone 3.44o both consis-
tent with cis-stereochemistry, correspond to -amino--hydroxy substrituted 
esters 3.40m and 3.40o with anti-configuration. 
 
 
Scheme 43. Oxazolidinones 3.44m and 3.44o. 
 
 
We reasoned that the relative stereochemistry could be a consequence of a 
intermolecular hydrogen bonding between the proton of the monoprotected 
amine and the carbonyl oxygen (Scheme 44, shaded in gray). This chelation 
action, as can be seen in the Newman projection, makes the Re-face open for 
the nucleophile attack. The transition state shows the direction of the attacking 
hydride and the formation of the product with the anti-configuration even more 
clearly. 
 
 
 
Scheme 44. Rationalization of the relative stereochemistry. 
 
 
The internal hydrogen bonding was confirmed when a substrate with tertiary 
amine 3.45 was synthesized (Scheme 45). The amine moiety contained both N-
Me and N-Boc groups and was thus unable to take the same conformation as the 
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substrates with a secondary amine. The reaction was supposed to follow the 
polar Felkin-Ahn model, depicted via Newman projection in Scheme 45. After 
subjecting 3.45 to the ATH conditions, product 3.46 with cis-configuration was 
afforded, in line with our reasoning. The configuration was confirmed by 
formation of oxazolidinone 3.47 and assessing the vicinal proton coupling 
constant JHH = 4.9 Hz, which is consistent with the cis-configuration. A similar 
action of mono- and diprotected amine moieties in -amino aldehydes have 
been noticed, where it was reasoned that the NHBoc substrate reacted via -
chelated conformer in the presence of a Lewis acid and the doubly protected 
substrates did not chelate.132 
 
 
Scheme 45. ATH of N-Me, N-Boc protected substrate. Rationalization of the relative 
stereochemistry. 
 
 
3.2.4. Substrate synthesis for ATH 
Several routes were explored in order to find a straightforward, high yielding 
method to afford substrates for the ATH experiments. Most of the aryl 
substrates 3.39a–g were made according to the route shown in Scheme 46. The 
commercially available diethyl aminomalonate 3.48 was treated with (Boc)2O 
to yield N-Boc protected compound, and after monosaponification the acid 3.49 
was afforded.133 This acid was then treated with acid chlorides 3.50a–m of 
choice to afford the substrates 3.39a–g. 
 
 
 
Scheme 46. Synthesis of ATH substrates 3.39a-g. 
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During the course of the work a higher yielding method was found and applied 
for the synthesis of the alkyl substrates 3.39l-o and 3.39a, 3.39p, r, s and also 
N-Me, N-Boc substrate 3.45 (Scheme 47). The glycine-O-methyl ester hydro-
chloride 3.51 was Cbz-protected in an aqueous environment in the presence of 
benzyl chloroformate and 2 N NaHCO3 to yield 3.52 in a good yield.134 Then 
3.52 was treated with acid chlorides 3.50l-o of choice in the presence of 
LiHMDS at -78 °C in good yields. The resulting imide 3.53l-o was subjected 
again to LiHMDS in the presence of DMPU for intramolecular migration of the 
variable carbonyl group from the nitrogen to the -carbon to afford the products 
3.39l-o.135 The Boc-protected substrates 3.39a, p, r, s were synthesized in the 
similar fashion (Scheme 47), apart from the protection of glycine 3.51 with 
Boc-group.136  Compared with the route described above in Scheme 46, these 
gave higher yields and should be preferred for the synthesis of all the substrates. 
A route where glycine 3.51 was first treated with the variable acid chloride and 
only then was protected with a Boc-group was also tried, but this rendered 
lower yields compared to when the glycine was protected first.  
 
 
 
Scheme 47. Synthesis of Cbz-protected substrates 3.39l-o for ATH and alternative route 
for Boc-protected substrates.  
 
 
An acylation route where the potassium salt of Schiff base 3.56 and the variable 
acetyl chloride 3.50 were stirred at –78 °C was also tried for Boc-protected 
substrates (Scheme 48),137 but was less effective in affording the end products 
in good yield compared to the aforementioned routes. 
 
 
 
 
Scheme 48. Alternative synthesis route for substrates. 
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3.3. Conclusions 
An enantioselective method was developed for the synthesis of anti--hydroxy-
-amino acid derivates by asymmetric transfer hydrogenation via dynamic 
kinetic resolution. The method was successfully demonstrated on a range of 
substrates in two different reaction media, without using high pressures or 
flammable gases. Firstly, a variety of aryl substrates were shown to afford 
excellent stereoselectivities and high yields in the azeotropic mixture of 
HCOOH and Et3N. The scope of the reduction was widened to alkyl substrates 
in water emulsions where sodium formate acted as a hydrogen donor. The 
asymmetric transfer hydrogenation in water emulsions is suitable for both aryl- 
and alkyl substrates and affords the products in high enantio- and diastereo-
selectivity and in high yields.  
 
 
3.4. Experimental 
Preparing the variable acid chlorides 3.50 for the substrates of ATH. 
General procedure starting from carboxylic acid: 
 
 
 
The acid (1.5 equiv.) was dissolved in SOCl2 (1.5 equiv.) and stirred at 80 °C 
for 1 h. The solution was then let to cool to rt and concentrated to dryness in 
vacuo. The afforded acid chloride was directly used in the acylation reaction 
without prior purification.  
 
Oxidation of an aldehyde to carboxyl acid:138 
 
 
 
The aldehyde (200 mg, 1.42 mmol) in acetone (30 mL) was added NaH2PO4  
(30 mL, aq. satd., pH 2) and cooled to 0 °C. Then the solution was added 2-
methyl-2-butene (500 mg, 7.12 mmol) and dropwisely a solution of NaCl2O2 
(257 mg, 2.84 mmol) in H2O (15 mL) at 0 °C. The reaction was stirred for 25 
min after which it was poured onto ice cool H2O (40 mL). The mixture was 
extracted three times with CH2Cl2. The collected organic phases were dried over 
MgSO4, filtrated and concentrated in vacuo. The crude was purified by column 
chromatography on silica (50% EtOAc in hexanes) to yield the acid as a desired 
product (208 mg, 91%). 
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This procedure was used also for preparing phenyl 3-Br and thionyl acid 
chlorides. 
 
Oxidation with Jones reagent:139 
 
 
 
The Jones reagent stock solution was prepared in the following way: To the 
stirred solution of CrO3 (2.1 g, 21 mmol) in H2O (5.3 mL) was added conc. 
H2SO4 (1.8 mL) and stirred at rt for 5 min.  
To the solution of substrate (150 mg, 0.89 mmol) in acetone (5 mL) was 
added the Jones reagent stock solution (0.9 mL) at 0°C and the reaction was 
stirred for 2 h. Then the reaction was added i-PrOH (2 mL) and poured into a 
separatory funnel after 5 min of stirring. After the mixture was then diluted with 
H2O and EtOAc, the phases were separated and the aqueous phase extracted 
once with EtOAc. The collected organic phases were dried over MgSO4, 
filtrated and concentrated in vacuo. The crude was purified by column 
chromatography on silica (50% EtOAc in hexanes) to yield the acid as expected 
product (157 mg, 90%). 
 
Synthesis of N-Me, N-Boc protected substrate 3.45: 
 
Compound 3.58140 (234 mg, 1.15 mmol) was dissolved in THF (10 mL) and the 
solution was cooled to 0 °C. Freshly prepared LDA solution (10 mL, 1.27 mmol) 
was added and the mixture was stirred for 2 h. Then the mixture was added 
dropwise to a benzoyl chloride 3.50a (147 L, 1.27 mmol) solution in THF  
(15 mL) at 0 °C. The reaction mixture was allowed to warm to room 
temperature overnight. After quenching with H2O (50 mL), the mixture was 
extracted with EtOAc (3x30 mL). The combined organic phases were dried 
over Na2SO4, filtered and concentrated in vacuo. The crude residue was purified 
by flash column chromatography (EtOAc in hexanes), product 3.45 was 
obtained as a clear oil (141.9 mg, 40%). 
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4. CONCLUDING REMARKS  
In this thesis two synthetic methods are discussed, the first incorporates kinetic 
resolution in a synthesis of an analogue to a natural compound, and the second 
focuses on a methodology study using dynamic kinetic resolution. In the first 
part, four aza- and two thio-analogues of the acetogenins are synthesized 
according to a modular route. Kinetic resolution of a terminal bis-epoxide 
affords a crucial intermediate and forges two remote stereocenters in high 
enantio- and diastereoselectivity. This intermediate forms a linker between the 
central heteroatom containing fragment and a terminal butenolide, which are 
deemed relevant in binding to the complex I in mitochondria. The preliminary 
cytotoxicity assays against HeLa cell line showed the higher potency of the aza-
analogues compared to the thio-analogues, although the cytotoxicities of all the 
synthesized analogues are lower than reported for the natural compounds. We 
believe this study offers a more facile approach for the synthesis of the 
acetogenins, allowing variation in the length of the linker and the nature of the 
central region, accompanied by excellent stereoselectivity. By creating novel 
analogues with varying bioactivities the study also contributes to the elucidation 
of the structure-activity relationship of the acetogenins. 
In the second part, the synthesis of anti--hydroxy--amino acid derivates is 
shown by asymmetric transfer hydrogenation via dynamic kinetic resolution. 
The method was conducted both in water emulsions using sodium formate as 
the hydrogen donor, and also in azeotropic mixture with triethylammonium 
formate as the reducing agent. The reduction in water media widened the scope 
to both aryl- and alkyl-substrates, and afforded the products with high enantio- 
and diastereoselecivity. It was found that the anti-selectivity in the case of 
monoprotected amines can be caused by the internal hydrogen bonding, absent 
in the substrate furnished with a dual protected amine moiety, affording the syn-
configuration. As the method uses water as a solvent, and can be conducted at 
room temperatures and in air atmospere, it can be considered as a facile and 
environmentally friendly method for synthesising these important building 
blocks en route to more complex bioactive molecules. 
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5. SUMMARY IN ESTONIAN 
Atsetogeniinide analoogide süntees. 
Asümmeetriline vesinikuülekanne -amido--keto estritele 
dünaamilise kineetilise resolutsiooni teel 
 
Selles töös käsitletakse kahte teemat, esimene kirjeldab kineetilise lahutamise 
meetodi kasutamist bioaktiivsete ühendite sünteesis ning teine keskendub 
metodoloogia uurimisele, mis kasutab dünaamilist kineetilist resolutsiooni. Töö 
esimseses osas näidatakse nelja asa- ja kahe tio-atsetogeniini analoogi sünteesi. 
Terminaalsete bis-epoksiidide kineetilise lahutamise meetodi rakendamisel 
saadakse kõrge enantio- ja diastereoselektiivsusega oluline vaheühend kahe 
kaugelasetseva kiraalse tsentriga. Sellest vaheühendist moodustub analoogis 
paiknev ‘linker’, mis ühendab heteroaatomeid sisaldavat fragmenti ja terminaal-
set butenoliidi. Esmased tsütotoksilisuse uuringud HeLa rakuliinis näitasid asa-
analoogide suuremat rakukasvu pärssivat mõju võrreldes tio-analoogidega, 
samas jäid mõlemad alla looduslike atsetogeniinide tsütotoksilisusele. Tänu 
sünteesitee modulaarsele iseloomule saab kergelt varieerida stereokeemiat ja 
vahetada heteroaatomeid sisaldavat tsentraalset fragmenti vastavalt soovitavale 
analoogile.  
Uurimistöö teises osas kirjeldatakse anti--amido--hüdroksü estrite sün-
teesi asümmeetrilise vesiniku ülekande teel läbi dünaamilise kineetilise resolut-
siooni. Aminohappe derivaate kasutatakse laialdaselt keerukamate bioaktiivsete 
molekulide sünteesil, kus kõrge stereoselektiivsus on tihti määrava tähtsusega. 
Selliste molekulaarsete ‘ehitusblokkide’ saamiseks on alati otsitud järjest 
efektiivsemaid ja loodussõbralikemaid sünteesimeetodeid. Meie väljatöötatud 
taandamistingimustes andsid nii arüül- kui ka alküülsubstraadid kõrge en-
antioselektiivsusega produkte, millel on anti-konfiguratsioon. Leiti, et sub-
straatidel, millel on mono-kaitstud amiin, võib anti-selektiivuse põhjustada 
molekuli-sisene vesiniksideme teke, mis kahe kaitsegrupiga tertsiaarsel amiinil 
puudub ja mille saadusel samadel tingimustel on syn-konfiguratsioon. Vesi-
emulsiooni tingimustes oli võimalik saavutada kõrgete stereoselektiivsuste ja 
saagistega produkte nii arüül- kui alküülühendite puhul ning reaktsioonid viidi 
läbi toatemperatuuril ja atmosfäärirõhul, seega võib meie väljatöötatud meetodit 
lugeda heaks alternatiiviks olemasolevatele meetoditele antud aminohapete 
derivaatide sünteesiks.  
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